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ABSTRACT

CHARACTERIZATION OF THE ROLES OF MUSCLE-SYNTHESIZED BRAINDERIVED NEUROTROPHIC FACTOR AND PRESYNAPTIC TYROSINE
RECEPTOR KINASE B IN MOTOR NEURON AXONAL TRANSPORT

By

Luke A. VanOsdol

Neurotrophins, such as brain-derived neurotrophic factor (BDNF), are small,
diffusible proteins essential for the development, survival, function, and plasticity of
neurons. Neurotrophin actions are primarily mediated by the tyrosine receptor kinase
(Trk) family of receptors (Patapoutian and Reichardt, 2001). BDNF binding to its
receptor, TrkB, results in autophosphorylation of tyrosine residues on the cytoplasmic
domain, leading to the activated form, phosphorylated-TrkB (p-TrkB). The BDNF-TrkB
complex is endocytosed into a specialized vesicle, called a signaling endosome, which
can induce a number of downstream signaling cascades locally, in the dendrites or distal
axon. Although primarily, the BDNF-TrkB signaling endosome is trafficked to the cell
soma via retrograde transport, where it initiates signaling pathways and causes changes in
gene expression (Ginty and Segal, 2002; Cohen et al., 2011). Retrograde axonal transport
is the mechanism by which signaling endosomes or cellular components packaged into
vesicles are carried from the distal terminals of neurons to the cell body by the motor
protein dynein (Maday et al., 2014). Disruption of this process is a hallmark of several
neuromuscular diseases including spinal and bulbar muscular atrophy (SBMA),
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Huntington’s disease (HD), and amyotropic lateral sclerosis (ALS; Morfini et al., 2009).
Because of the importance of BDNF-TrkB signaling for neuronal health and the initiation
of retrograde transport, mice with reduced or absent muscle-synthesized BDNF were
hypothesized to exhibit reduced TrkB activation at the neuromuscular junction (NMJ) as
well as impairments in retrograde axonal transport (Mitchell et al., 2012). The Cre/lox
gene technology system was used to generate experimental mice missing skeletal musclesynthesized BDNF. Gastrocnemius (gastroc) muscle tissue was harvested from 120d
animals, and the expression of TrkB and p-TrkB were assessed in the pre- and
postsynaptic terminals of NMJs. Presynaptic TrkB expression was not statistically
different between groups, while postsynaptic TrkB was significantly reduced in the
heterozygous (HE) and homozygous (HO) knockout animals compared to controls. Preand postsynaptic p-TrkB expression was significantly reduced in both knockout mice
compared to controls. These results suggest significantly decreased TrkB activation in
gastroc-associated motor neurons of muscle-derived BDNF knockout animals. Sciatic
nerve ligation experiments were performed on 120d mice to assess axonal transport
mechanisms. Expression of the structural protein α-tubulin was evaluated as an internal
control, and accumulation of TrkB and p-TrkB, along with c-Jun-amino-terminal kinaseinteracting protein 3 (JIP3) and dynactin (DCTN1), two essential transport complex
adaptor proteins, were assessed on the proximal and distal sides of ligation. Uniform
levels of α-tubulin expression across groups indicated a high level of consistency
throughout the immunohistochemical (IHC) staining and data collection procedures. On
the proximal side of ligation, TrkB and DCTN1 accumulation were equivalent between
HE knockout and control mice, while accumulation of p-TrkB and JIP3 was significantly
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reduced in HE animals compared to controls, suggesting potential dysfunctions in
anterograde axonal transport in HE knockouts. Distally, p-TrkB, JIP3, and DCTN1
accumulation were significantly reduced in HE mice compared to controls, indicating
markedly impaired retrograde transport mechanisms. In HO knockout animals,
accumulation of TrkB, p-TrkB, JIP3, and DCTN1, both proximally and distally, were
significantly decreased when compared to control mice. These data suggest severe
impairments in anterograde and retrograde axonal transport processes due to a lack of
muscle-synthesized BDNF. Additionally, because of equivalent accumulation in HE and
HO knockouts, the proper functioning of JIP3 was noted to exhibit some type of
threshold requirement for the levels of muscle-BDNF expression.
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW

Neurotrophins and neurotrophin signaling
Neurotrophins are a family of small, diffusible proteins that strongly influence
and regulate the development, survival, function, and plasticity of neurons. In the
mammalian nervous system, neurotrophins are derived from a common ancestral gene,
and thus are similar in sequence and structure (Hallböök, 1999; Huang and Reichardt,
2001). The known neurotrophins are nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5;
Hallböök, 1999; Kaplan and Miller, 2000; reviewed in Huang and Reichardt, 2001;
Reichardt, 2006). In addition to sequence and structural homologies, the individual
neurotrophin genes also contain multiple promoters. The protein product of each gene is
comprised of a signal sequence and a prodomain, followed by the mature neurotrophin
sequence. The gene products, called proneurotrophins, must undergo proteolytic cleavage
to form the mature neurotrophin protein. Unsurprisingly, this is an important posttranscriptional point of regulation that both limits and adds to the specificity of
neurotrophin action (Lee et al., 2001b; Reichardt, 2006). Functions of the neurotrophin
prodomains include promoting the folding of the mature domain and sorting of
neurotrophins to either constitutive or regulated secretory pathways. Furthermore, the
highly conserved nature of the prodomains suggest they may mediate additional
biological actions and have an important role in intracellular processing (Heinrich and
Lum, 2000; reviewed in Lu et al., 2005).
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Neurotrophins exert their actions by binding to two types of membrane receptors
– the high-affinity tyrosine receptor kinase or tropomyosin receptor kinase (Trk) family
of receptors, and the lower-affinity p75 neurotrophin receptor (p75NTR), a member of
the tumor necrosis factor receptor superfamily (McAllister et al., 1999; Kaplan and
Miller, 2000; Patapoutian and Reichardt, 2001). Past work has shown that
proneurotrophins primarily bind p75NTR, while the mature neurotrophins bind to the Trk
receptors (Lu et al., 2005). The Trk receptor isoforms have a degree of specificity as to
the particular neurotrophin they will bind. For example, NGF has a high affinity for the
tropomyosin-related kinase A (TrkA) receptor. BDNF and NT-4/5 bind to the TrkB
receptor. NT-3, on the other hand, primarily activates the TrkC receptor, but is also
recognized by TrkA and TrkB receptors, although with less affinity than the primary
ligands (Huang and Reichardt, 2001; Patapoutian and Reichardt, 2001). Several studies
have shown that p75NTR can increase both the affinity and specificity of Trk receptorneurotrophin interactions and induce apoptosis in neurons and other cell types when Trk
activation is reduced or absent (Lee et al., 2001a, 2001b). The p75NTR and Trk receptors
orchestrate and modify neuronal responses to neurotrophins and are often located on the
same cell. Trk receptors, however, generally transmit signals that lead to neural growth
and synaptic expansion, while p75NTR signaling often leads to cellular hypotrophy and
apoptosis (reviewed in Kaplan and Miller, 2000; Lu et al., 2005). The pro-survival effects
of mature neurotrophins have been well established (reviewed in Lu et al., 2005).
Administration of mature neurotrophins to specific brain regions can rescue neuronal loss
associated with aging or induced by chemical or mechanical insults, while deletion of
specific neurotrophin genes leads to the loss of certain populations of neurons (reviewed
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in Lu et al., 2005). Additionally, neurotrophins are important in both developing and
mature neural circuits. These studies are discussed in more detail below.
There are many stages involved in the development of neural circuits, and
neurotrophins have critical roles in each. The stages of circuit development include
neural stem cell survival and differentiation, axon-dendrite differentiation, axonal growth
and guidance, synapse formation and maturation, and refinement of developing circuits
(reviewed in Park and Poo, 2012). Embryonic neural stem cells express Trk receptors and
p75NTR (Park and Poo, 2012). Treating cultured cortical and hippocampal neural stem
cells from mouse embryos with recombinant BDNF and NGF promotes cell survival and
differentiation into neurons (Ahmed et al., 1995; Lachyankar et al., 1997; Shetty and
Turner, 1998; reviewed in Park and Poo, 2012). During axon-dendrite polarization of
cultured hippocampal neurons, exposure of an undifferentiated neurite to extracellular
BDNF promotes its differentiation into an axon (Shelly et al., 2007). In cultured neurons,
an extracellular gradient of neurotrophins causes chemotropic turning of axonal growth
cones (Gundersen and Barrett, 1979; Song et al., 1997). This guidance may also occur in
vivo. In developing mouse limb buds, sensory axons can be directed toward implanted
beads containing NGF, BDNF, NT-3, or NT-4/5 (Tucker et al., 2001). In mature
pyramidal cells in developing cortical slices, dendritic growth is increased by treatment
with BDNF, but inhibited by NT-3 in layer 4. In layer 6, these effects are reversed
(McAllister et al., 1997). In the developing optic tectum of Xenopus laevis tadpoles, in
vivo infusion of exogenous BDNF promotes synaptogenesis; this phenomenon may be
attributed to the BDNF-induced increases in axon and dendrite arborization of retinal
ganglion cells (Cohen-Cory and Fraser, 1995; McAllister et al., 1995, 1996; Alsina et al.,
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2001). The actions of neurotrophins in the development of neural circuits are reviewed in
further detail by Park and Poo, 2012.
In addition to the numerous roles neurotrophins play in neural development, these
proteins also serve many regulatory functions in mature circuits (reviewed in Park and
Poo, 2012). Neurotrophins released at the synapse can rapidly change the efficacy of
synaptic transmission and the capacity of activity induced by long-term potentiation and
long-term depression (reviewed in Park and Poo, 2012). Neurotrophins mediate changes
in neuronal excitability through their effects on the expression and function of voltagegated ion channels (reviewed in Park and Poo, 2012).
Neurotrophin-mediated activation of Trk receptors regulate numerous pathways
such as proliferation and survival of neurons, axonal and dendritic growth, assembly and
remodeling of the cytoskeleton, membrane trafficking and fusion, and synapse formation
and plasticity (reviewed in Huang and Reichardt, 2003). The importance of Trk receptor
activation is underscored by the loss of specific cell populations in Trk gene knockouts
(reviewed in Lu et al., 2005). TrkB-deficient mice show reduced survival of newly
generated hippocampal granule cells (Sairanen, 2005; Bergami et al., 2008).
Additionally, mice lacking TrkB in hippocampal neural progenitor cells have impaired
proliferation and neurogenesis (Bath et al., 2008; Li et al., 2008). Ligand activation of
Trk receptors results in autophosphorylation of tyrosine residues on the cytoplasmic
domain, leading to the activated form – phosphorylated-Trk (p-Trk). Of the 10
evolutionarily conserved tyrosines in their cytoplasmic domains, three are present in the
autoregulatory loop of the kinase domain that mediate tyrosine kinase activity.
Phosphorylation of these residues further enhances receptor activation (reviewed in
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Huang and Reichardt, 2001). Trk receptor signaling is promoted by phosphorylation of
the other tyrosine residues, which creates docking sites for adapter proteins containing
phosphotyrosine-binding or src-homology-2 motifs (reviewed in Huang and Reichardt,
2001). The main pathways induced by Trk receptor activation include the Ras, Rac, and
phosphatidylinositol 3-kinase (PI3-K) cascades, the phospholipase C-γ1 (PLC-γ1)
pathway, as well as their downstream effectors (reviewed in Huang and Reichardt, 2003;
Reichardt, 2006). PI3-K activation of protein kinase B suppresses cell death by inhibiting
the apoptotic activities of forkhead and B-cell leukemia/lymphoma 2 (BCL2)-associated
death protein (Datta et al., 1997; del Peso et al., 1997; Brunet et al., 1999; reviewed in Lu
et al., 2005; Reichardt, 2006). Ras stimulation of mitogen-activated protein kinase (also
known as extracellular signal-regulated kinase, ERK) signaling cascades produces a
number of downstream effects, including increased activity or expression of antiapoptotic proteins such as BCL2 and the transcription factor cyclic AMP responsive
element-binding protein (CREB; Aloyz et al., 1998; Riccio et al., 1999; reviewed in Lu et
al., 2005; Reichardt, 2006). PLC-γ1-dependent generation of inositol triphosphate and
diacylglycerol (DAG) leads to mobilization of Ca2+ stores and activation of Ca2+- and
DAG-regulated protein kinases, including protein kinase C. Studies have shown that the
endocytosis and transfer of Trk receptors to different membrane compartments, in
conjunction with the localization of many adapter proteins to specific membrane
compartments, modulates the efficiency and duration of Trk-mediated signaling (Geetha
et al., 2005; reviewed in Reichardt, 2006).
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Importance of brain-derived neurotrophic factor (BDNF)
BDNF is the most widely expressed and well-characterized neurotrophin in the
mammalian brain (Anastasia and Hempstead, 2014). Despite its name, BDNF is
synthesized in a number of other tissue types besides the brain, including skeletal muscle,
endocrine tissues, and male- and female-specific tissues such as the testis and fallopian
tubes (Funakoshi et al., 1995; Matthews et al., 2009; Halievski et al., 2015). Studies have
shown that proBDNF is the main form secreted from cells, and mature BDNF is
generated via proteolytic cleavage by extracellular proteases. BDNF, proBDNF, and the
cleaved prodomain are all biologically active (Lu et al., 2005; Anastasia and Hempstead,
2014). In addition to the pro-survival effects of BDNF signaling, BDNF has been shown
to rapidly modulate the synthesis, metabolism, and release of neurotransmitters such as
glutamate (reviewed in Park and Poo, 2012). Moreover, BDNF-TrkB signaling regulates
the organization of the cytoskeleton, influences cell motility and growth cone behavior,
and modulates synaptic function and plasticity (reviewed in Reichardt, 2006; Park and
Poo, 2012).
BDNF acts as an anterograde signal protein, binding to post-synaptic receptors in
both the central nervous system (CNS) and peripheral nervous system (Zhou and Rush,
1996; Altar et al., 1997; Conner et al., 1997). Additionally, BDNF promotes axon
development and growth in both developing and polarized neurons in an autocrine
fashion by acting on the cell that secreted it (Cheng et al., 2011). BDNF also acts as a
retrograde signal protein and can be secreted from target (postsynaptic) tissue to
subsequently bind to presynaptic receptors (Ginty and Segal, 2002). After binding and
activating its presynaptic receptor, often the BDNF-TrkB complex is endocytosed and
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then transported to the cell body in retrograde signaling endosomes by the cytoskeletal
motor protein dynein (Ginty and Segal, 2002; Howe and Mobley, 2005; Cosker and
Segal, 2014; Ayloo et al., 2017). At the cell body, the BDNF-TrkB complex activates
downstream signaling cascades and can induce changes in gene expression (Ginty and
Segal, 2002). Thus, BDNF activation of TrkB can initiate signaling cascades (mentioned
previously) at a postysynaptic cell, at the presynapse, and in the cellular perikarya (Ginty
and Segal, 2002).
Irregularities in the levels and activities of a variety of neurotrophins have been
implicated in a number of neurological disorders. BDNF is understood as one of the
major regulators of synaptic plasticity, neuronal survival and differentiation, and as such,
is a leading target for drug therapies (Zuccato and Cattaneo, 2009). In the early 2000s, a
single-nucleotide polymorphism in the BDNF gene that leads to a valine → methionine
substitution at position 66 in the prodomain (Val66Met; BDNFMet) was linked to memory
impairments, reductions in hippocampal volume, and altered susceptibility to disorders
such as Alzheimer’s disease, Parkinson’s disease, depression, eating disorders, and
bipolar disorder (Chao et al., 2006; Anastasia and Hempstead, 2014). The Val66Met
substitution impairs BDNF release from neurons by altering the structure of its
prodomain, which, in a p75NTR-dependent manner, ultimately decreases Rac signaling
leading to neuronal growth cone reduction and a loss in synaptic density (Anastasia and
Hempstead, 2014).
A number of studies performed in postmortem humans have demonstrated that
BDNF mRNA expression is reduced in the substantia nigra of Parkinson’s disease
patients and in affected cortical regions in Alzheimer’s disease (Holsinger et al., 2000;
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Howells et al., 2000; Liu et al., 2005). While homozygous universal knockout of the
BDNF gene in mice leads to embryonic death and rare chances of survival, heterozygous
BDNF knockouts display enhanced inter-male aggressiveness, hyperphagia, and
significant weight gains in early adulthood (Ernfors et al., 1994; Lyons et al., 1999). In
addition, a reduction in BDNF mRNA is a hallmark of several neurodegenerative
diseases including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA),
spinal and bulbar muscular atrophy (SBMA), Huntington’s disease (HD), Alzheimer’s
disease, and Parkinson’s disease (Holsinger et al., 2000; Howells et al., 2000; Zuccato et
al., 2001; Jiang et al., 2005; Liu et al., 2005; Zuccato and Cattaneo, 2009; Halievski et al.,
2015).
While the role of BDNF in the neurons and glia of the brain and spinal cord has
been studied extensively, its actions in other tissue types are less understood. In the late
1990s and early 2000s, researchers noted that physical activity preserved cognitive
function in elderly populations, promoted functional recovery after traumatic CNS injury,
and induced neurogenesis in the adult CNS, likely by increasing neurotrophin production
in select regions of the brain and spinal cord (Neeper et al., 1995; Jones et al., 1999;
Kramer et al., 1999; Kempermann et al., 2000; Gomez-Pinilla et al., 2001, 2002).
Researchers found that application of BDNF to severed spinal cord promoted
regenerative motor neuron growth and stimulated hindlimb stepping (Bregman et al.,
1997; Jakeman et al., 1998; Yang and Arnold, 2000; Gomez-Pinilla et al., 2002; Yang et
al., 2004). Gómez-Pinilla et al. (2002) demonstrated that voluntary exercise increased
BDNF and CREB mRNA expression in spinal cord and soleus muscle of rats. In the
spinal cord, CREB mRNA expression increased in proportion to BDNF mRNA levels
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(Gomez-Pinilla et al., 2002). In the same study, researchers noted that paralysis of the
soleus muscle using botulinum toxin type A reduced BDNF mRNA levels below control
levels and prevented any increases in spinal cord and muscle ensuing from physical
activity (Gomez-Pinilla et al., 2002). The results obtained by Gómez-Pinilla et al. (2002)
suggest that basal levels of neuromuscular activity are required to maintain normal levels
of BDNF in the neuromuscular system and ultimately, the potential for neuroplasticity.
Another study emphasizing the existence of a signaling pathway between physical
activity and neuronal changes was conducted by Gazula and colleagues in 2004. In this
experiment, the dendritic structure of motor neurons of rats with an intact spinal cord was
compared to rats with a complete spinal cord transection (SCT) and rats with a SCT that
were also engaged in daily exercise consisting of actively moving paralyzed hindlimbs
through the motions of walking. The motor neurons of animals with SCT showed
considerable atrophy, displaying loss of dendritic membrane and branching when
compared to rats with intact spinal cords (Gazula et al., 2004). In contrast, none of these
detrimental changes were observed in motor neurons of rats with SCT who underwent the
subsequent exercise regime (Gazula et al., 2004). In a second experiment by the same
group, researchers noted that increased exercise in rats with intact spinal cords had
minimal effects on dendritic morphology, suggesting an upper limit of activity-dependent
dendritic growth (Gazula et al., 2004). The results obtained by these experiments, along
with those of Gómez-Pinilla et al., suggest the influence of muscle-derived signaling in
the maintenance of motor neurons as well as recovery following injury (Gomez-Pinilla et
al., 2001, 2002; Gazula et al., 2004).
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The importance of muscle-synthesized BDNF signaling in the health and
maintenance of innervating neurons is also highlighted by studies investigating the spinal
nucleus of the bulbocavernosus (SNB). This sexually dimorphic group of motor neurons
is found near the midline of the ventral horn in the lower lumbar spinal cord of rats. In
males, SNB motor neurons innervate the bulbocavernosus (BC) and levator ani (LA)
muscles which attach to the penis and control penile reflexes and copulation (Breedlove
and Arnold, 1980; Cooke et al., 1998; Ottem et al., 2007). The SNB motor neurons in
males have a high degree of dendritic arborization, and their development and
maintenance are dependent on androgens as is evidenced by dendritic retraction
following castration (Kurz et al., 1986; Goldstein et al., 1990; Ottem et al., 2007).
Following castration, androgen replacement protocols restore the dendritic arborization
(Kurz et al., 1986; Goldstein et al., 1990; Ottem et al., 2007). Additionally, axotomy of
adult SNB motor neurons decreases their levels of BDNF, which suggests that BC and
LA muscles are a source of BDNF for these cells (Yang and Arnold, 2000). Axotomy
results in significant size reductions of SNB somata, while BDNF treatment at the site of
the severed axons counteracts this effect (Yang and Arnold, 2000). In these androgensensitive neurons, BDNF treatment alone does not restore the dendrites of SNB motor
neurons, and requires the combinatory action of testosterone replacement to achieve
dendritic restoration (Yang et al., 2004). An early study emphasizing the role of BDNF
signaling from BC and LA muscles in the modulation of SNB motor neurons showed that
disruption of retrograde signal transport, not lack of muscle activity, was responsible for
reductions in androgen receptor expression in SNB motor neurons (reviewed in Ottem et
al., 2013).
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Importance of muscle-synthesized BDNF
Building on these studies, the Ottem research laboratory has employed the use of
a transgenic mouse model to further the understanding of the role of muscle-synthesized
BDNF. By utilizing the Cre/lox gene technology system (described in more detail in
Chapter 2), mice with a tissue-specific loss, or knockout, of one or both copies of the
BDNF gene in skeletal muscle were generated and used for experiments. These mice
display a behavioral phenotype that is similar to that observed in other animal models of
neuromuscular diseases such as ALS or SBMA (Moser et al., 2013). For example, the
adult heterozygous (MuscleBDNF+/-) and homozygous (MuscleBDNF-/-) knockout mice
struggle to remain on a suspended rotating rod, have reduced grip strength, and have
higher clasping scores compared to wild type control animals (WT; MuscleBDNF+/+). In
addition, histological analyses revealed significant muscle pathology in the
gastrocnemius (gastroc) muscle of heterozygous and homozygous knockout mice. These
mice exhibit hypertrophic and hypotrophic fibers, fiber splitting, centralized nuclei, and
an overall age-independent, but progressive loss of fibers that was apparent when
comparing muscles from 30d, 90d, 120d, 180d, and 210d animals (Figures 1 and 2). The
myopathology is not as pervasive in other muscles examined, which may be attributed to
the varying composition of fiber types in each muscle. For example, in the slow-twitch
muscle of the soleus, 30d homozygous knockouts were the only group to display
increased myopathology when compared to control animals at any older age (Figures 3
and 4).
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Figure 1. Gastrocnemius (gastroc) muscle fiber pathology in 120d transgenic mice
missing muscle-synthesized BDNF. Gastroc muscle sections (40 µm) were stained with
Haemotoxylin and Eosin (H&E) and photomicrographs were taken at 10X. (A) Wild type
control (WT; MuscleBDNF+/+) fibers displayed no splitting and nuclei were localized in the
periphery of the fibers. (B) Heterozygous knockout (MuscleBDNF+/-) muscle fibers showed
fiber splitting (triangle) and centralized nuclei (arrows). (C) In addition to fiber splitting
(triangles) and centralized nuclei (arrows), homozygous knockout (MuscleBDNF-/-) muscle
tissue exhibited considerable hyper- and hypotrophy. Adapted from Taisto et al. (2013).
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Figure 2. Ontogeny of gastrocnemius (gastroc) myopathology in MuscleBDNF+/+,
MuscleBDNF+/-, and MuscleBDNF-/- mice. In addition to the significant increases in mean
percentage of gastroc fibers displaying myopathology in heterozygous and homozygous
knockouts, there was an age-independent, but progressive escalation of myopathology in
these animals (*** = p<0.001). Adapted from Taisto et al. (2013).

Figure 3. Soleus myopathology in 120d transgenic mice missing muscle-synthesized
BDNF. Muscle sections (40 µm) were H&E stained and photomicrographs were taken at
10X. (A) Wild type control (WT; MuscleBDNF+/+) fibers displayed no splitting and nuclei
were localized in the periphery of the fibers. (B) Heterozygous (MuscleBDNF+/-) and (C)
homozygous (MuscleBDNF-/-) knockout muscle fibers exhibited some fiber splitting
(triangle) and centralized nuclei (arrows). Adapted from Taisto et al. (2013).
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Figure 4. Ontogeny of soleus myopathology in MuscleBDNF+/+, MuscleBDNF+/-, and
MuscleBDNF-/- mice. Significant increases in mean percentage of soleus muscle fibers
displaying myopathology were recorded only for 30d homozygous (MuscleBDNF-/-)
knockouts compared to control animals (*** = p<0.001). Adapted from Taisto et al.
(2013).

In addition to the myopathology recorded in transgenic mice missing musclesynthesized BDNF, the morphology of gastroc and soleus motor neurons were also
investigated using a series of histological and immunohistochemical (IHC) assays to
determine soma size and dendritic arborization of the associated lumbar motor neurons.
Utilizing IHC, proteins associated with the neuromuscular junction (NMJ) could be
compared between WT animals and those with reduced or absent muscle-synthesized
BDNF. By labeling vesicular acetylcholine transporter (VAChT; a presynaptic marker),
and the postsynaptic acetylcholine receptor (AChR) using α-bungarotoxin (α-BTX; a
postsynaptic marker), the presynapse and postsynapse of the NMJ were visualized and
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then evaluated. Comparing immunofluorescence labeling of gastroc-associated NMJs
between the experimental groups of 120d mice revealed a significant reduction in the
presynaptic surface area in homozygous knockout (MuscleBDNF-/-) mice (Figure 5A),
whereas there were no significant differences in the postsynaptic surface area between
genotypes (Figure 5B). Fragmentation of the NMJ, which manifests naturally as a result
of aging and/or dystrophy, was found to have a significantly higher occurrence in
heterozygous and homozygous knockout animals compared to controls (Figures 6 and 7).
These results may be due to impaired TrkB signaling, which has been shown to induce
disassembly and fragmentation of postsynaptic AChR clusters (Gonzalez et al., 1999;
Kulakowski et al., 2011).

Figure 5. Mean surface area (µm2) of presynaptic vesicular acetylcholine transporter
(VAChT) and postsynaptic acetylcholine receptor (AChR; labeled with α-BTX)
immunofluorescence in gastroc-associated neuromuscular junctions of 120d animals. (A)
There was a marked decrease in presynaptic VAChT surface area in homozygous
(MuscleBDNF-/-) knockouts compared to controls (*** = p<0.001). (B) There were no
significant differences in postsynaptic AChR surface area between animal groups.
Adapted from Taisto et al. (2013).
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Figure 6. Representative Imaris (Bitplane) rendering of neuromuscular junction (NMJ)
fragmentation in mice missing muscle-synthesized BDNF. Presynaptic VAChT is shown
in cyan, while postsynaptic AChR (labeled with α-BTX) is in red. (A) Control
(MuscleBDNF+/+) animals displayed complete, intact NMJs. (B) Heterozygous
(MuscleBDNF+/-) and (C) homozygous (MuscleBDNF-/-) knockout mice exhibited genotypedependent increases in NMJ fragmentation. Adapted from Taisto et al. (2013).

Figure 7. Multiple sample predictor model for gastroc NMJ fragmentation in mice
missing muscle-synthesized BDNF. Probability of gastroc-associated NMJ fragmentation
was significantly higher in heterozygous (MuscleBDNF+/-) and homozygous (MuscleBDNF-/-)
knockout mice compared to controls (MuscleBDNF+/+; ** = p<0.01; *** = p<0.001).
Adapted from Taisto et al. (2013).
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Cellular pathologies have been recorded in gastroc-associated motor neurons in
transgenic mice missing muscle-synthesized BDNF (Pomeroy, 2013). Notably, in lumbar
motor neurons of 30d mice, MuscleBDNF-/- animals showed significantly increased BDNF
immunofluorescence compared to control (MuscleBDNF+/+) and heterozygous knockout
mice (MuscleBDNF+/-; Figure 8A). In contrast, 120d heterozygous animals exhibited a
marked increase in BDNF immunofluorescence compared to the other groups (Figure
8B). Furthermore, mean motor neuron cell soma area was significantly diminished in
heterozygous and homozygous knockouts compared to controls in both 30d and 120d
animals (Figures 9A and 9B, respectively). In another experiment, the fluorescent tracer
molecule Fluoro-Gold™ (Fluorochrome LLC, Denver, CO), also known as
hydroxystilbamidine, was utilized to assess lumbar motor neuron morphology. Following
injection into gastroc muscle, Fluoro-Gold™ is endocytosed by innervating motor
neurons and carried back to the cell body via retrograde axonal transport, where it fills
the soma and dendrites (Schmued and Fallon, 1986). Thus, mean Fluoro-Gold™-labeled
dendritic diameter and length were able to be quantified and compared for experimental
groups at 30d and 120d. As depicted in Figure 10, the mean dendritic diameter was
significantly reduced in 30d homozygous knockout animals compared to other groups,
while at 120d, both heterozygous and homozygous knockout animals had reduced
dendritic diameter compared to controls (Pomeroy, 2013). The mean dendritic length of
gastroc-associated lumbar motor neurons was significantly reduced in 30d heterozygous
and homozygous knockout animals compared to controls (Figure 11; Pomeroy, 2013). At
120d, there were general increases in mean dendritic length for each genotype, but again,
dendritic length was significantly diminished in MuscleBDNF+/- and MuscleBDNF-/- mice
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compared to control animals (Figure 11; Pomeroy, 2013). However, these reductions in
dendritic length and diameter may have been due to impairments in retrograde axonal
transport rather than abnormalities in motor neuron morphology, as discussed later
(Pomeroy, 2013; Dangremond, 2016).

Figure 8. Mean BDNF immunofluorescence in lumbar motor neurons of 30d and 120d
mice. (A) At 30d, lumbar motor neurons of homozygous (MuscleBDNF-/-) knockouts
exhibited a marked increase in somal BDNF immunofluorescence compared to controls,
whereas no significant changes were observed in heterozygous (MuscleBDNF+/-) mice
compared to control animals (*** = p<0.001). (B) In contrast, at 120d, somal BDNF
immunofluorescence was significantly higher in MuscleBDNF+/- mice compared to
controls, while there were no notable differences in MuscleBDNF-/- animals compared to
controls (*** = p<0.001). Adapted from Pomeroy (2013).
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Figure 9. Mean lamina X motor neuron cell soma area (µm2) in 30d and 120d
MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/- mice. (A) At 30d and (B) 120d, both
heterozygous and homozygous knockouts displayed significant reductions in area
compared to controls (** = p<0.01; *** = p<0.001). Adapted from Pomeroy (2013).

Figure 10. Mean dendritic diameter (µm) of Fluoro-Gold™ labeled gastroc-associated
lumbar motor neurons in MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/- mice. At 30d,
only homozygous knockouts exhibited significant reductions in dendritic diameter
compared to control mice (*** = p<0.001). Whereas at 120d, both heterozygous and
homozygous knockout animals displayed diminished dendritic diameter compared to
controls (*** = p<0.001). Adapted from Pomeroy (2013).
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Figure 11. Mean dendritic length (µm) of Fluoro-Gold™ labeled gastroc-associated
lumbar motor neurons in 30d and 120d MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/mice. At 30d, both heterozygous and homozygous knockouts displayed decreased
dendritic length compared to controls (*** = p<0.001). By 120d, there was an overall
increase in dendritic length, however, hetero- and homozygous knockout mice still
exhibited significant reductions in dendritic length compared to controls (*** = p<0.001).
Adapted from Pomeroy (2013).

Axonal transport mechanisms
Disruption of retrograde axonal transport in motor neurons is a hallmark of
several neuromuscular diseases including SBMA, HD, and ALS (Morfini et al., 2009).
Retrograde transport is the process by which proteins, mitochondria, and other cellular
components are packaged into vesicles in the distal synaptic terminals of neurons, and
then retrogradely transported toward the cell body by the cytoskeletal motor protein
(cytoplasmic) dynein (Goldstein and Yang, 2000). Cytoplasmic dynein is a large and
complex molecule composed of two heavy chains (DYNC1H1), which fold to form the
motor domains and utilize ATP hydrolysis to generate force, as well as a number of
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intermediate, light intermediate, and light chains, which are thought to function primarily
in cargo association and regulation (Chevalier-Larsen and Holzbaur, 2006). A schematic
of this complex is shown in Figure 12. In addition to cellular cargo, dynein is responsible
for the retrograde movement of neurotrophin signaling endosomes, including BDNF,
through the long axons of motor neurons (Cosker and Segal, 2014). Moreover, studies
have shown that dynein is able to transport cargo and signaling endosomes both into and
out of dendrites, further emphasizing the importance of this motor protein (Kapitein et al.,
2010; Ayloo et al., 2017).
Recently, research has begun to more-closely examine the nuanced mechanics of
long-range transit of cellular cargo by dynein and kinesin motors. One such study
revealed that kinesin-1 moves cargo less efficiently in hippocampal dendrites compared
to axons, suggesting a compartment-based specificity for this motor protein (Ayloo et al.,
2017). Conversely, dynein was noted to effectively navigate both axons and dendrites
(Ayloo et al., 2017). Additionally, dynein-dependent transport in axons and dendrites was
increased by dynamic microtubule plus ends, which has been shown to be the result of an
enhanced interaction of dynactin with tyrosinated microtubules (McKenney et al., 2016;
Nirschl et al., 2016; Ayloo et al., 2017).
Dynactin, an accessory or activator complex, helps dynein bind cargo and
signaling endosomes, has been demonstrated to be required for most dynein functions in
vivo, and is important for the initiation of axonal transport (Chevalier-Larsen and
Holzbaur, 2006; Moughamian and Holzbaur, 2012; Moughamian et al., 2013; Cosker and
Segal, 2014; McKenney et al., 2014, 2016; Nirschl et al., 2016). Dynactin is a large,
complex molecule composed of 11 different subunits (Chevalier-Larsen and Holzbaur,
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2006). The most notable aspect of dynactin is the actin-like filament subunit, actin-related
protein Arp1, which forms the base of the complex (Chevalier-Larsen and Holzbaur,
2006). Projecting from this filament is a dimer of an extended coil-coil protein, p150Glued,
which binds directly to dynein and microtubules (Chevalier-Larsen and Holzbaur, 2006).
A schematic of dynactin associated with the cytoplasmic dynein motor complex is shown
below in Figure 12.
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Figure 12. Cytoplasmic Dynein and Kinesin Power Axonal Transport. Schematic diagram
of the microtubule motor proteins cytoplasmic dynein and kinesin. Cytoplasmic dynein
transports cargo in the retrograde direction toward the minus ends of microtubules
whereas kinesin transports cargo in the anterograde direction toward the plus ends.
Cytoplasmic dynein is a large multimeric protein complex comprising of two heavy chain
subunits (red) that possess microtubule binding and ATPase activity, two intermediate
chains (yellow), two light intermediate chains (indigo) and an assortment of light chains
(light pink, green, orange). Dynactin, a large multisubunit protein complex of comparable
size to cytoplasmic dynein, is proposed to link the dynein motor to cargo and/or increases
its processivity. The largest dynactin subunit, p150Glued (turquoise), forms an elongated
dimer that interacts with the dynein intermediate chain and binds to microtubules via a
highly conserved CAP-Gly motif at the tip of globular heads. The dynactin subunit p50
(dark pink) occupies a central position linking p150Glued to cargo. The conventional
kinesin holoenzyme, also known as kinesin-1, is a heterotetramer comprising two Khc
subunits (red) with microtubule binding and ATPase domains, a central coiled stalk, and
a tail domain that interacts with two Klc subunits (green). Klcs may mediate cargobinding via an intermediate scaffold protein (blue) that binds a cargo transmembrane
protein (yellow). Adapted from Duncan and Goldstein (2006).

A number of studies have demonstrated the importance of neurotrophin signaling
via Trk receptors for the initiation of retrograde transport. Yano et al. (2001) performed
coimmunoprecipitation experiments in vivo to demonstrate that Trk receptors, including
TrkB, can form a complex with the light and intermediate chains of dynein. In the same
study, researchers employed sciatic nerve ligations to show marked accumulation of
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TrkB with light and intermediate chains of dynein, suggesting a direct interaction
between TrkB and the dynein complex (Yano et al., 2001). Dynein has been shown to be
required for the proper retrograde transport of BDNF-TrkB complexes, however, other
motors may also contribute to this motility (Ghiretti et al., 2016; Ayloo et al., 2017).
Endosomes containing neurotrophin-Trk receptor complexes associate with the dynein
motor complex, and this is known as the signaling endosome model (Figure 13). The
major function of BDNF-TrkB signaling endosomes is to modulate gene expression
following active transport to the soma (Heerssen et al., 2004; Cohen et al., 2011; Ayloo et
al., 2017). The signaling endosome model is supported by a number of studies
demonstrating that after formation, the neurotrophin-Trk complex is internalized into
endosomes through a clathrin-mediated endocytotic pathway, and transported
retrogradely toward the cell soma (Ginty and Segal, 2002; Heerssen et al., 2004; Maday
et al., 2014; Ghiretti et al., 2016; Ayloo et al., 2017). Additional studies have shown that
TrkB activation of the Erk1/2 kinase pathway recruits cytoplasmic dynein to signaling
endosomes for retrograde axonal transport (Mitchell et al., 2012). Moreover, inhibition of
Erk1/2 reduces the motility of TrkB-containing endosomes and the extent of their
colocalization with dynein in axons (Mitchell et al., 2012). High-resolution imaging has
also demonstrated dynein-based vesicular transport of activated Trk (p-Trk) receptors
within rat sciatic nerve axons in a retrograde fashion, as vesicles accumulate distal to a
ligation site (Bhattacharyya et al., 2002). One study utilized kinase-dead and truncated
variants of TrkB to show that only activated receptors undergo retrograde transport
(Heerssen et al., 2004).
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Other studies have described the significance of adaptor proteins, such as c-Jun
NH2-terminal kinase-interacting protein 3 (JIP3), in the regulation of Trk receptor axonal
transport and augmentation of neurotrophin signaling by directly linking Trk with motor
protein complexes (Huang et al., 2011). Additionally, the binding of JIP3 to kinesin-1
light chain has been shown to be essential for anterograde TrkB transport and BDNFinduced retrograde TrkB signaling (Sun et al., 2017).

Figure 13. The ‘signaling endosome’ model. Trk receptors on distal axons are activated
upon binding to neurotrophin. The ligand-receptor complex internalizes through clathrinmediated endocytosis. Some of the vesicles become specialized endosomes that serve as
platforms for continued Trk signaling and are transported retrogradely to the cell body
using a dynein-dependent and microtubule-dependent transport mechanism. The vesicleassociated Trk receptor remains autophosphorylated and capable of promoting a unique
set of signals upon arrival at the cell bodies. These include PI3K and Erk5. Adapted from
Ginty and Segal (2002).

Axonal transport deficits in disease
Defects in axonal transport may explain the heightened vulnerability of long
projection neurons, such as motor neurons, in diseases such as SBMA, HD, and ALS
(Morfini et al., 2009; Kemp et al., 2011). The cell body of motor neurons is the primary
site of both metabolic and degradative functions, and thus requires continuous, efficient
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transport of materials to and from the cell soma (Chevalier-Larsen and Holzbaur, 2006;
Duncan and Goldstein, 2006). Mutations that affect the cytoplasmic dynein motor
complex, specifically the gene encoding DYNC1H1, have been shown to cause spinal
muscular atrophy (SMA) and Charcot-Marie-Tooth disease (Garrett et al., 2014). One
study in particular demonstrated that one such mutation, in a mouse model of SMA,
altered signaling endosome transport kinetics as well as Erk1/2-cFos signaling in a celltype specific manner, suggesting a plausible explanation for how mutations in
ubiquitously expressed DYNC1H1 cause neuron-specific disease (Garrett et al., 2014).
This theme, ubiquitous expression of a causative gene resulting in selective
neuronal death and dysfunction in disease-specific areas of the CNS, is common, and
suggests similar molecular mechanisms for these diseases (Katsuno et al., 2006). For
example, HD is caused by an abnormal polyglutamine (polyQ) expansion in huntingtin
protein (HTT), and is characterized by the loss of striatal and cortical neurons (Liot et al.,
2013). Similarly, spinal and bulbar muscular atrophy (SBMA, or Kennedy’s disease) is
characterized by the loss of bulbar and spinal motor neurons, and is caused by an
expansion of the polyQ tract in the first exon of the androgen receptor (AR) gene
(Katsuno et al., 2006). Both of these diseases have been linked to disruptions in
retrograde transport, as discussed below.
Studies have shown that vesicular transport deficits, particularly of BDNF, are a
major aspect of the cellular pathology in HD, as BDNF is not produced by striatal
neurons, but is synthesized in the cortex and transported to the striatum by corticostriatal
projecting neurons (Altar et al., 1997; Liot et al., 2013). While reducing cortical
production of BDNF leads to striatal degeneration, recovery of axonal transport or
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secretion of BDNF enhances BDNF release and neuronal survival, suggesting that BDNF
from cortical neurons activate TrkB receptors at striatal dendrites to promote striatum
survival (Liot et al., 2013). In a set of experiments by Liot and colleagues, TrkB was
demonstrated to bind and colocalize with HTT and dynein, silencing HTT reduced
vesicular transport of TrkB in striatal neurons, and, in HD, the polyQ expansion in HTT
altered the binding of TrkB-containing vesicles to microtubules and reduced transport,
suggesting HTT as a critical mediator of TrkB trafficking (Liot et al., 2013).
Impaired retrograde transport has also been implicated in SBMA, where the
mutant AR gene causes aggregation of the deviant polyQ protein and inhibits the function
of transcription factors and coactivators as well as other cellular operations (Katsuno et
al., 2006; Kemp et al., 2011). A recent study demonstrated deficiencies of retrograde
transport in spinal motor neurons in both a knock-in and a myogenic transgenic mouse
model of SBMA, implying that disease triggered in muscle can impair retrograde
transport of cargo in motor neuron axons (Kemp et al., 2011). In the same study,
researchers found that treatment of diseased muscles with vascular endothelial growth
factor reversed the deficit in transport, further supporting the hypothesis of impaired
retrograde signaling (Kemp et al., 2011). In another mouse model of SBMA, researchers
noted accumulation of neurofilament-H (NF-H), a major component of the cytoskeleton,
and synaptophysin (SYN), an integral membrane glycoprotein occurring in presynaptic
vesicles of neurons, similar to the intramuscular accumulation observed in skeletal
muscle of SBMA patients (Katsuno et al., 2006). In this transgenic mouse model carrying
human pathogenic AR, researchers utilized Fluoro-Gold™ labeling and sciatic nerve
ligation protocols to demonstrate impaired retrograde axonal transport (Katsuno et al.,
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2006). Additionally, significant reductions in mRNA levels of dynactin 1 (DCTN1),
resulting from pathogenic AR-induced transcriptional dysregulation, was recorded in the
SBMA mice (Katsuno et al., 2006). Researchers reported that castration prevented
nuclear accumulation of pathogenic AR, thus reversing the pathological events
mentioned previously (Katsuno et al., 2006).
Amyotrophic lateral sclerosis (ALS) is yet another neurodegenerative disease
with potential underlying impairments in axonal transport. There are two categories of
ALS. Familial ALS (fALS) is caused by heritable factors and accounts for roughly 10%
of all cases, whereas sporadic ALS (sALS) has no known causes and seemingly arises
randomly. Both types produce similar pathological markers, including progressive
muscle weakness, atrophy, and spasticity due to degeneration and death of upper and
lower motor neurons (Boillée et al., 2006). Denervation of the respiratory muscles and
diaphragm is typically the cause of death (Boillée et al., 2006). The selective
vulnerability of motor neurons in ALS has been suggested to be a combination of several
factors including protein misfolding, oxidative stress, excitotoxicity, impaired axonal
transport, mitochondrial dysfunction, inflammation, and neurotrophin deprivation (Jiang
et al., 2005; Boillée et al., 2006). Non-neuronal neighboring cells further enhance damage
within motor neurons via inflammatory responses that accelerate disease progression
(Boillée et al., 2006).
In both forms of ALS, defective axonal transport is a prime candidate for the
pathogenesis observed in human patients and animal models (Jiang et al., 2005; Bilsland
et al., 2010). Approximately 20-30% of fALS cases are linked to mutations in the
copper/zinc superoxide dismutase 1 (SOD1) gene (Jiang et al., 2005). There are over one
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hundred known disease-causing SOD1 mutations distributed throughout all five exons,
and with few exceptions, all mutations are dominant (Boillée et al., 2006). Mice and rats
expressing mutant forms of human or mouse SOD1 exhibit progressive motor neuron
degeneration and serve as useful animal models for ALS, as fALS and sALS are
pathologically and clinically similar (Bruijn et al., 2004; Boillée et al., 2006). SOD1 is a
cytosolic enzyme that converts superoxides to water or hydrogen peroxide, and is both
abundantly and ubiquitously expressed (Boillée et al., 2006). Surprisingly, it is not the
loss of SOD1 function that confers toxicity to mutants, as deletion of the SOD1 gene in
mice does not lead to motor neuron disease (Reaume et al., 1996). Rather, the diseaseassociated mutations are known to destabilize the protein and cause it to become
misfolded (Boillée et al., 2006; Sau et al., 2007). Misfolded SOD1 triggers a cascade of
events, including protein accumulation, axonal transport alterations, and mitochondrial
and/or proteasome dysfunctions (Sau et al., 2007). These events may indirectly lead to
overproduction of reactive oxygen species and caspase activation, and may be
intercorrelated (Sau et al., 2007).
An early study by Williamson and Cleveland demonstrated that the reduction of
axonal transport is a very early feature of the toxicity in motor neurons mediated by ALSlinked SOD1 mutants (Williamson and Cleveland, 1999). More recently, Bilsland and
colleagues emphasized the presymptomatic appearance of deficits in axonal transport
using an in vivo assay that permitted characterization of axonal transport in single axons
of intact sciatic nerves (Bilsland et al., 2010). ALS patients and mice expressing mutant
SOD1 have been shown to display neurofilament accumulations, which are suggested to
arise from defects in slow anterograde axonal transport (Boillée et al., 2006; Bilsland et
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al., 2010). Additionally, embryonic motor neurons from transgenic mice expressing
human mutant SOD1G93A have been shown to exhibit variations in fast axonal transport
(Boillée et al., 2006; Bilsland et al., 2010). The studies conducted by Bilsland and
associates revealed significant slowing of retrograde transport at each disease stage
(presymptomatic, early symptomatic, symptomatic, late symptomatic) in SOD1 G93A mice
compared to wild type (WT) and SOD1WT mice (Bilsland et al., 2010). Additionally,
there was significantly reduced TrkB accumulation in ligated sciatic nerve of SOD1G93A
mice compared to WT controls (Bilsland et al., 2010).

Ottem laboratory axonal transport studies
The Ottem laboratory, building on previous research, has conducted a set of
experiments delving into potential axonal transport defects in transgenic mice missing
muscle-synthesized BDNF (Dangremond, 2016). In these experiments, based on a
protocol by Katsuno et al., 2006, sciatic nerve ligations were conducted on 30d and 120d
homozygous knockout (MuscleBDNF-/-), heterozygous knockout (MuscleBDNF+/-), and wild
type (MuscleBDNF+/+) animals (Dangremond, 2016). In this experiment, accumulation of
three proteins of interest were evaluated at the areas immediately proximal and distal to
the ligation site. The labeled proteins were dynactin, SYN, and phosphorylated NF-H
(NF-H-P). The structural protein NF-H is delivered from the cell soma to the distal axon
in vesicles by the motor protein kinesin. As NF-H is transported anterogradely down the
axon, it gets increasingly phosphorylated, which diminishes the protein’s affinity for
kinesin and enhances its affinity for dynein (Motil et al., 2007). Thus, NF-H was
expected to associate with kinesin motors in anterograde transport complexes, and was
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not investigated. Alternatively, NF-H-P was hypothesized to be associated with dynactin
in retrograde transport complexes, and was labeled as a protein of interest in this
experiment.
Assessment of NF-H-P accumulation on the distal side of the ligation site in
MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/- animals revealed no significant
differences in 30d mice, while there were significant reductions in NF-H-P accumulation
in MuscleBDNF-/- animals compared to others at 120d (Figure 14; Dangremond, 2016).
Similarly, aggregation of dynactin on the distal side of the ligation site was significantly
diminished in MuscleBDNF-/- mice compared to control at 120d (Figure 15; Dangremond,
2016). There were no significant differences in the accumulation of SYN between groups
in 30d and 120d animals (Figure 16; Dangremond, 2016).

Figure 14. Mean surface area (µm2) of phosphorylated neurofilament-H (NF-H-P)
immunofluorescence immediately distal to sciatic nerve ligation site in 30d and 120d
mice. (A) At 30d, there were no significant differences in mean NF-H-P surface area
between MuscleBDNF+/+, MuscleBDNF+/-, or MuscleBDNF-/- mice. (B) At 120d, only
homozygous knockouts exhibited significant reductions in mean NF-H-P
immunofluorescence surface area compared to controls (** = p<0.01). Adapted from
Dangremond (2016).
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Figure 15. Mean surface area (µm2) of dynactin immunofluorescence in the portion
immediately distal to sciatic nerve ligation site in 120d MuscleBDNF+/+, MuscleBDNF+/-, and
MuscleBDNF-/- mice. There were significant reductions only in homozygous knockouts
compared to control animals (** = p<0.01). Adapted from Dangremond (2016).
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Figure 16. Mean surface area (µm2) of synaptophysin (SYN) immunofluorescence in
portion immediately distal to sciatic nerve ligation site in 30d and 120d MuscleBDNF+/+,
MuscleBDNF+/-, and MuscleBDNF-/- mice. At 30d, no significant differences in SYN surface
area were recorded across genotypes, however, there was a trending increase in SYN
immunofluorescence. At 120d, there were no significant changes in mean surface area.
Adapted from Dangremond (2016).

There were no differences in NF-H-P accumulation on the proximal side of the
ligation site between MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/- animals (Figure 17;
Dangremond, 2016). Conversely, there were significant increases in dynactin
accumulation at the proximal side of the ligation site in MuscleBDNF+/- and MuscleBDNF-/mice (Figure 18; Dangremond, 2016). Similar to NF-H-P, there were no significant
changes in SYN accumulation at the proximal site between animals (Figure 19;
Dangremond, 2016).
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Figure 17. Mean surface area (µm2) of NF-H-P immunofluorescence immediately
proximal to ligation site in 120d MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/- mice.
There were no significant differences across genotypes. Adapted from Dangremond
(2016).
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Figure 18. Mean surface area (µm2) of dynactin immunofluorescence immediately
proximal to ligation site in 120d MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/- mice.
Mean surface area of dynactin was significantly increased in heterozygous and
homozygous knockout animals compared to controls (* = p<0.05). Adapted from
Dangremond (2016).
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Figure 19. Mean surface area (µm2) of synaptophysin (SYN) immunofluorescence
immediately proximal to sciatic nerve ligation site in 120d MuscleBDNF+/+, MuscleBDNF+/-,
and MuscleBDNF-/- mice. There were no significant differences in SYN
immunofluorescence between genotypes. Adapted from Dangremond (2016).

In addition to sciatic nerve ligation studies, experiments that further investigated
the possibility that retrograde transport is diminished in mice missing muscle-synthesized
BDNF were conducted (Dangremond, 2016). The Ottem lab assessed levels of NF-H-P –
a protein that, under normal cellular conditions, should be associated with dynein and
retrogradely transported to the cell body for recycling – in gastroc-associated NMJs of
these transgenic mice (Dangremond, 2016). An accumulation of NF-H-P in the axons of
gastroc-associated motor neurons would suggest potential deficits in retrograde transport.
Indeed, although there were no differences in levels of NF-H-P between MuscleBDNF+/+,
MuscleBDNF+/-, and MuscleBDNF-/- mice at 30d (Figure 20A), there were significant
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increases in both the heterozygous and homozygous knockout animals compared to
controls at 120d (Figure 20B; Dangremond, 2016).

Figure 20. Mean surface area (µm2) of NF-H-P immunofluorescence in distal gastrocassociated motor neuron axons and presynaptic terminals of 30d and 120d MuscleBDNF+/+,
MuscleBDNF+/-, and MuscleBDNF-/- mice. (A) No significant differences in NF-H-P
immunolabeling were observed in 30d animals. (B) At 120d, heterozygous and
homozygous knockouts exhibited significant increases in mean NF-H-P surface area
compared to controls (** = p<0.01). Adapted from Dangremond (2016).

Experimental aims
Given that dynactin accumulation on the distal sciatic ligation site is reduced in
MuscleBDNF-/- animals (Figure 15) and NF-H-P accumulation is increased in both 120d
MuscleBDNF+/- and MuscleBDNF-/- mice (Figure 20B), it would appear that mice missing
muscle-synthesized BDNF have disruptions in retrograde transport (Dangremond, 2016).
Because of the prevalence of retrograde transport dysfunction in neurodegenerative
diseases such as ALS, and the pathological similarities of these mice to other animal
models of neurodegenerative diseases, the goal of present studies was to further
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investigate and characterize the retrograde transport deficits recorded in these mice
(Katsuno et al., 2006; Moser et al., 2013; Dangremond, 2016). As BDNF-TrkB signaling
has been shown to play such a critical role in motor neuron health and axonal transport,
the expression of TrkB and its activated form, p-TrkB, was assessed in gastroc-associated
NMJs of 120d MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/- mice (Ginty and Segal,
2002; Mitchell et al., 2012). Additionally, a sciatic nerve ligation protocol (adapted from
Katsuno et al., 2006 and Dangremond, 2016) was used to evaluate the composition and
density of axonal transport complexes in 120d mice missing muscle-synthesized BDNF
to further address the retrograde transport deficits reported in these animals
(Dangremond, 2016). IHC was utilized to label JIP3, an adaptor protein, α-tubulin, a
structural protein, dynactin, TrkB, and p-TrkB in ligated sciatic nerves.
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CHAPTER TWO: GENERATION OF EXPERIMENTAL TRANSGENIC
ANIMALS

Introduction
For all experiments, the Cre/lox system was used to generate tissue-specific
BDNF gene knockout animals. To accomplish this, two separate colonies of transgenic
mice, originally obtained from Jackson Laboratories (Bar Harbor, Maine), were
maintained. In the first strain, the coding region of the BDNF gene was flanked by two
34bp loxP sequences (floxed BDNF), thus providing the recognition sites for the Cre
recombinase protein. The second colony carried the Cre transgene driven by the human
skeletal actin promoter on the X-chromosome, and consequently, only expressed Cre
recombinase in skeletal muscle cells. Crossing and back-crossing offspring from the two
colonies results in transgenic mice wherein BDNF is knocked out only in skeletal muscle.
See Figure 21 for a schematic description of the transgenic crossing system. Figure 22
depicts the polymerase chain reaction (PCR) results from various tissue types confirming
the loss of BDNF only in skeletal muscle in these transgenic animals. For each
experiment, a group of wild-type control (MuscleBDNF+/+), heterozygous knockout
(MuscleBDNF+/-), and homozygous knockout (MuscleBDNF-/-) animals were used.

39

Figure 21. Diagram detailing the tissue-specific targeting of BDNF in skeletal muscle
using the Cre/lox system. A mouse carrying the Cre recombinase transgene driven by the
human skeletal actin promoter is crossed with a mouse that has BDNF flanked by loxP
recognition sites (floxed BDNF). Because of the specificity of the human skeletal
promoter, the Cre recombinase enzyme is only expressed in skeletal muscle. Thus,
animals positive for both the Cre transgene and floxed BDNF will have the coding region
of the BDNF gene (exon 9) excised only in skeletal muscle. See Figure 22 for PCR
confirmation of muscle-specific loss of BDNF in skeletal muscle in these transgenic
mice.
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Figure 22. Results of BDNF gene PCR assay confirming loss of BDNF in skeletal muscle
using the Cre/lox system. PCR amplification products were electrophoresed on an
agarose gel, stained with ethidium bromide, and visualized with UV light. (A) Control
(MuscleBDNF+/+) mice had the full-length coding region of BDNF (2050bp) amplified in
skeletal muscle, kidney, heart, and brain tissue. (B) The BDNF amplification product is
truncated (975bp) only in the skeletal muscle of homozygous knockout mice
(MuscleBDNF-/-).

Methods
Animal husbandry
Animals were maintained according to the National Institutes of Health (NIH)
Guidelines for the Care and Use of Laboratory Animals and approved by the Institutional
Animal Care and Use Committee (IACUC) of Northern Michigan University (Appendix
A). Animals were housed in the temperature- and light-controlled animal facility at
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Northern Michigan University with a 14:10 hour light-dark schedule (lights on from
07:00 to 21:00) and had access to food (Mazuri® Rodent Chow, Land O’ Lakes Purina
Feed LLC, Richmond, IN) and water ad libitum.

Genotyping of experimental animals
Each animal was earpunched for identification, and the resultant tissue was used
for genotyping procedures. Genotyping was accomplished through the use of two
separate PCR reactions – one for the detection of the floxed BDNF gene and one for the
presence of the Cre transgene. Visualization of the PCR amplification products was
attained using agarose gel electrophoresis. Two primers were employed in the PCR used
to verify the presence (or lack) of floxed BDNF alleles in each animal. The forward
(1846) primer sequence was TGTGATTGTGTTTCTGGTGAC, and the reverse (1847)
primer sequence was GCCTTCATGCAACCGAAGTATG. The 5’ forward primer
hybridized to a segment upstream of the first loxP site, and the 3’ reverse primer
hybridized to a segment internal to the BDNF gene coding region. The use of these two
primers allowed for amplification of both floxed and non-floxed BDNF. The resulting
amplification products were differentiated based on size: floxed BDNF products were
487bp whereas non-floxed were 419bp (shown in Figure 23).
A different set of primers was employed in the PCR evaluating whether the Cre
transgene was present or absent in each animal. The forward (1084) primer sequence for
the Cre transgene was GCGGTCTGGCAGTAAAAACTATC. The reverse (1085) primer
sequence was GTGAAACAGCATTGCTGTCACTT. In addition, another pair of primers
specific for a housekeeping gene (interleukin 2, IL2) were used as a positive control
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alongside the pair of primers targeting the Cre transgene. The IL2 primer sequences used
were CTAGGCCACAGAATTGAAAGATCT (forward; 7338), and
GTAGGTGGAAATTCTAGCATCATCC (reverse; 7339). After amplification, the PCR
products were visualized on an agarose gel, with all animals displaying a 300bp band
representing the IL2 housekeeping gene, while only those animals heterozygous for the
Cre transgene show a 100bp amplification band. An example of typical results for the
Cre transgene PCR can be found below in Figure 24.

1000bp
500bp
400bp
300bp

+/- +/+ +/+ +/- +/+ -/- +/+ +/-

487bp
419bp

200bp

100bp

Figure 23. Photograph of BDNF gene PCR amplification products ran on 3% agarose gel,
stained with ethidium bromide, and visualized using UV light. The first lane displays a
100bp ladder (Axygen® 100bp DNA ladder, product #M-DNA-100bp, Corning, Inc.). In
the remaining lanes, the upper band (487bp) represents floxed BDNF, while the lower
band (419bp) is non-floxed BDNF.
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1000bp
500bp
300bp
200bp
100bp

300bp
100bp
+/- +/- +/- +/- -/- +/-

-/-

+/- +/-

Figure 24. Photograph of Cre transgene PCR amplification products electrophoresed on a
1% agarose gel and stained with ethidium bromide, visualized using UV light. The first
lane contains a 100bp ladder (Axygen® 100bp DNA ladder, product #M-DNA-100bp,
Corning, Inc.). In the other lanes, the upper band (300bp) corresponds to amplification of
a housekeeping gene (IL2) all animals have, while the lower band (100bp) represents the
Cre transgene.

Breeding scheme for heterozygous knockout animals
After determining genotypes using the PCR techniques described above in
Figures 23 and 24, animals with loxP-flanked (floxed) BDNF (BDNFloxP+/+, Cre-/-) were
crossed with animals expressing the Cre transgene (BDNFloxP-/-, Cre+/-; F1 crosses, Figure
25). The F1 offspring derived from these crosses were either heterozygous for both the
floxed BDNF and Cre recombinase transgene (BDNFloxP+/-, Cre+/-) or heterozygous for
the floxed BDNF and missing Cre (BDNFloxP+/-, Cre-/-). Males that were heterozygous for
both floxed BDNF and Cre (BDNFloxP+/-, Cre+/-; referred to throughout as MuscleBDNF+/mice) were used as heterozygous knockouts in experiments, while the females of this
genotype (BDNFloxP+/-, Cre+/-) were used as F2 breeders to generate control and
homozygous knockout animals. See Figure 25 for reference.
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Breeding of homozygous knockout and control mice
Females heterozygous for floxed BDNF and the Cre transgene (BDNFloxP+/-,
Cre+/-) were crossed with males expressing floxed BDNF (BDNFloxP+/+, Cre-/-). The
resulting male F2 offspring homozygous for floxed BDNF and heterozygous for the Cre
transgene (BDNFloxP+/+, Cre+/-; referred to throughout as MuscleBDNF-/-) were used as
homozygous knockout animals in experiments, while those homozygous for floxed
BDNF and lacking the Cre transgene (BDNFloxP+/+, Cre-/-; referred to throughout as
MuscleBDNF+/+) were used as control animals. See Figure 25 below for reference.
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BDNFloxP+/+ Cre-/-

BDNFloxP-/- Cre+/-

F1

BDNFloxP+/- Cre+/-

BDNFloxP+/- Cre-/-

HE KO (♂) and F2 breeders (♀)

♀

♂

BDNFloxP+/- Cre+/-

BDNFloxP+/+ Cre-/-

F2

BDNFloxP+/+ Cre+/-

BDNFloxP+/+ Cre-/-

HO KO (♂)

CO (♂)

BDNFloxP+/- Cre+/-*

BDNFloxP+/- Cre-/-

Figure 25. Diagram of the breeding scheme used to generate experimental animals. In the
F1 crosses, floxed BDNF mice (BDNFloxP+/+, Cre-/-) were mated with mice carrying the
Cre transgene (BDNFloxP-/-, Cre+/-) to generate heterozygous knockout (HE KO) animals
(MuscleBDNF+/-, circled in purple). Heterozygous KO males were used in experiments,
while the females were used in F2 crosses with floxed BDNF males to generate
homozygous knockout (HO KO) animals (MuscleBDNF-/-, circled in red) and wild-type
control (CO) animals (MuscleBDNF+/+, circled in blue).

46

CHAPTER THREE: ASSESSMENT OF TRKB AND P-TRKB EXPRESSION IN
GASTROC-ASSOCIATED NMJS OF MICE MISSING MUSCLE-SYNTHESIZED
BDNF

Introduction
Neurotrophins are important for the development, maintenance, and survival of
neurons, and their actions are mediated by Trk receptors (Huang and Reichardt, 2001). Of
particular interest is BDNF activation of TrkB, which is important in the initiation of
retrograde transport (Mitchell et al., 2012). Specifically, this ligand-receptor interaction
recruits cytoplasmic dynein to signaling endosomes for retrograde axonal transport
(Ginty and Segal, 2002; Mitchell et al., 2012). Mice missing muscle-synthesized BDNF
display a number of myopathological features such as hyper- and hypotrophic fibers,
fiber splitting, centralized nuclei, age-independent loss of muscle fibers, and gastrocassociated NMJ fragmentation (Pomeroy, 2013; Dangremond, 2016). These transgenic
mice also exhibited reduced dendritic Fluoro-Gold™ labeling in gastroc-associated
lumbar motor neurons (Pomeroy, 2013).
Studies attempting to determine whether reduced dendritic labeling was due to
dendritic atrophy or reduced retrograde transport focused on NF-H-P, a protein
ubiquitously transported retrogradely to the cell body for recycling (Dangremond, 2016).
These experiments found significant accumulation of NF-H-P in the axons and
presynaptic terminals of gastroc-associated motor neurons in transgenic mice missing
muscle-synthesized BDNF (Figure 20; Dangremond, 2016). These results suggested that
disruption of retrograde transport, rather than dendritic atrophy, accounted for reduced
Fluoro-Gold™ labeling. Further, sciatic nerve ligation studies revealed significantly
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decreased accumulation of both NF-H-P and dynactin on the distal side of the ligation
site in these transgenic mice (Figures 14 and 15, respectively; Dangremond, 2016).
Together, these experiments suggest that mice-missing muscle-synthesized BDNF have
deficits in retrograde transport.
As BDNF-TrkB signaling is important for initiating the formation of retrograde
transport complexes, the first aim of this study was to assess the expression and
phosphorylation state of TrkB in gastroc-associated NMJs. To do this, antibodies against
TrkB and its activated form, phosphorylated-TrkB (p-TrkB), were employed alongside
antibodies targeting vesicular acetylcholine transporter (VAChT) to label the presynapse,
and α-BTX to label the acetylcholine receptors (AChR) in the postsynapse.

Methods
Animals
Animals in this experiment were maintained according to the NIH Guidelines for
the Care and Use of Laboratory Animals and approved by the IACUC of Northern
Michigan University (Appendix A). A total of 22 male mice at 120d of age were used in
these studies because all previous Ottem laboratory studies utilized males. Mice were
bred from existing colonies originally purchased from Jackson Laboratories (Bar Harbor,
Maine). For this experiment, seven wild type (WT) control (MuscleBDNF+/+) mice, eight
heterozygous knockout (MuscleBDNF+/-) mice, and seven homozygous knockout
(MuscleBDNF-/-) mice were used. Animals were housed in the temperature- and lightcontrolled animal facility at Northern Michigan University with a 14:10 hour light-dark
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schedule (lights on from 07:00 to 21:00), and had access to food (Mazuri® Rodent Chow,
Land O’ Lakes Purina Feed LLC, Richmond, IN) and water ad libitum.

Tissue harvest and processing
At age 120d, mice were anesthetized via inhalation of IsoThesia™ (isoflurane,
Henry Schein® Animal Health, Dublin, OH), and the gastroc muscle was removed from
the left leg. The muscle was flash frozen, mounted on Tissue-Tek® OCT compound
(Sakura® Finetek USA, Inc., Torrance, CA), and kept on dry ice until storage at -80 °C.
Immediately after the gastroc was harvested, mice were euthanized using an overdose of
sodium pentobarbital (250 mg/kg; Sigma-Aldrich®, St. Louis, MO) via intraperitoneal
(IP) injection. Muscles were sectioned longitudinally at 40 µm using a Leica CM1850
Cryostat and mounted onto subbed slides, then alternately processed using
immunohistochemical assays to label for TrkB or p-TrkB. This tissue harvest protocol
was used for roughly half of the animals (n=3) in each group.

Alternate method of tissue harvest and processing
At 120d of age, mice were anesthetized via inhalation of IsoThesia™ (isoflurane,
Henry Schein® Animal Health, Dublin, OH) and euthanized via IP injection of sodium
pentobarbital (250 mg/kg; Sigma-Aldrich®, St. Louis, MO). Tissues were fixed via
intracardial perfusion with 25 mM phosphate-buffered saline (PBS; 3 mM monobasic
sodium phosphate, 22.1 mM dibasic sodium phosphate, 152.3 mM sodium chloride)
followed by 4% paraformaldehyde (in 25 mM PBS). Following fixation, the left gastroc
muscle was removed, flash frozen, mounted on Tissue-Tek® OCT compound (Sakura®
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Finetek USA, Inc., Torrance, CA), and stored at -80 °C. Muscles were sectioned
longitudinally at 40 µm using a Leica CM1850 Cryostat and mounted onto subbed slides,
then alternately processed using immunohistochemical assays to assess TrkB or p-TrkB
expression. This tissue harvest protocol was used for half of the animals (n=4) in each
group, and yielded superior sectioning results.

TrkB immunohistochemistry (IHC)
To visualize TrkB expression at the NMJ, muscle sections were chemically crosslinked to subbed slides by incubation in paraformaldehyde (4% in 1:5 0.2 M monobasic:
0.2 M dibasic sodium phosphate buffer, pH 7.4) for 15 min and then rinsed with 1X PBS
(140 mM sodium chloride, 2.7 mM potassium chloride, 1.5 mM monobasic potassium
phosphate, 8 mM dibasic sodium phosphate heptahydrate). After incubating 1 hour with
blocking buffer (10% normal donkey serum, 0.2% Triton® X-100, 0.01% sodium azide
in 1X PBS), the tissue was incubated overnight with anti-TrkB (1:500, rabbit polyclonal
antibody, ab18987; Abcam, Cambridge, MA) and anti-VAChT (1:500, goat polyclonal
antibody, sc-7717; Santa Cruz® Biotechnology, Inc., Dallas, TX) in blocking buffer. The
tissue was washed with 1X PBS and incubated for 1 hour with the secondary antibody
solution (1X PBS, 0.01% sodium azide, 0.2% Triton® X-100, and secondary antibodies
indicated in Table 1). The tissue was rinsed with 1X PBS, allowed to dry, then
coverslipped using Vectasheild® Mounting Medium with DAPI (Vector Laboratories,
Inc., Burlingame, CA) to prevent quenching, and slides were stored in the dark at 4 °C.
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Table 1. Different secondary antibody labeling schemes used for TrkB gastroc IHC.
Fluorescent dye Secondary
Secondary
Secondary
preparation #1
preparation #2
preparation #3
Alexa Fluor® α-BTX (B13422)
Donkey anti-rabbit
Donkey anti-rabbit
488
(711-545-152)
(711-545-152)
Alexa Fluor® Donkey anti-rabbit
α-BTX (B13423)
Donkey anti-goat
594 (711-585-152)
(705-585-003)
Alexa Fluor® Donkey anti-goat
Donkey anti-goat
α-BTX (B35450)
647 (705-605-003)
(705-605-003)
Three different secondary antibody labeling schemes were used for gastroc TrkB IHC.
Product numbers are included with each labeling fluorophore. All α-BTX secondaries
were used at 1:200 and obtained from Molecular Probes® Life Technologies™ (Eugene,
OR). All anti-rabbit and anti-goat secondary antibodies were used at 1:150 and purchased
from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).

p-TrkB IHC
To visualize p-TrkB expression at the NMJ, muscle sections were chemically
cross-linked to subbed slides by incubation in paraformaldehyde (4% in 0.2 M phosphate
buffer, pH 7.4) for 15 min and then rinsed with 1X PBS. After incubating 1 hour with
blocking buffer (10% normal donkey serum, 0.2% Triton® X-100, 0.01% sodium azide
in 1X PBS), the tissue was incubated overnight with anti-p-TrkB (1:500, Tyr816, rabbit
polyclonal antibody, ABN1381; MilliporeSigma, Temecula, CA) and anti-VAChT
(1:500, goat polyclonal antibody, sc-7717; Santa Cruz® Biotechnology, Inc., Dallas, TX)
in blocking buffer. The tissue was washed with 1X PBS and incubated for 1 hour with the
secondary antibody solution (1X PBS, 0.01% sodium azide, 0.2% Triton® X-100, and
secondary antibodies shown below in Table 2). The tissue was rinsed with 1X PBS,
allowed to dry, then coverslipped using Vectasheild® Mounting Medium with DAPI
(Vector Laboratories, Burlingame, CA) to prevent quenching, and slides were stored in
the dark at 4 °C.
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Table 2. Different secondary antibody labeling schemes used for p-TrkB gastroc IHC.
Fluorescent dye Secondary
Secondary
Secondary
preparation #1
preparation #2
preparation #3
Alexa Fluor® α-BTX (B13422)
Donkey anti-rabbit
Donkey anti-rabbit
488
(711-545-152)
(711-545-152)
Alexa Fluor® Donkey anti-rabbit
α-BTX (B13423)
Donkey anti-goat
594 (711-585-152)
(705-585-003)
Alexa Fluor® Donkey anti-goat
Donkey anti-goat
α-BTX (B35450)
647 (705-605-003)
(705-605-003)
Three different secondary antibody labeling schemes were used for gastroc p-TrkB IHC.
Product numbers are included with each labeling fluorophore. All α-BTX secondaries
were used at 1:200 and obtained from Molecular Probes® Life Technologies™ (Eugene,
OR). All anti-rabbit and anti-goat secondary antibodies were used at 1:150 and purchased
from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).

Imaging, data collection, and analysis
Photomicrographs were collected at 60X using an Olympus Fluoview FV1000
laser scanning confocal microscope. Scanning speed, aspect ratio, and step size were set
at 20 µs/pixel, 800x800, and 0.44 µm, respectively. Image X, Y, and Z coordinate limits
were adjusted to include entire neuromuscular junctions in the final Z-stack. A minimum
of 45 junctions were imaged for each animal in the three experimental groups.
Photomicrographs were uploaded into Bitplane’s Imaris 3D rendering computer software
(Concord, MA) and, using the surface tool, 3D surfaces were created for the α-BTX,
VAChT, and TrkB (or p-TrkB) immunofluorescent channels (post-synapse, pre-synapse,
and receptor localization, respectively). Colocalization between TrkB and VAChT
surfaces, and TrkB and α-BTX surfaces, were rendered and exported as number of voxels
per NMJ. Colocalization between p-TrkB and VAChT surfaces, and p-TrkB and α-BTX
surfaces, were generated and quantified as number of voxels per NMJ. Examples of the
rendered immunofluorescence and colocalization surfaces for TrkB and p-TrkB can be
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found in Figures 26 and 27, respectively. One-way analysis of variance (ANOVA) and
post hoc Bonferroni procedure t-tests were used to compare data for the groups.

A.

B.

C.

D.

Figure 26. Assessment of TrkB expression in gastroc-associated NMJs of 120d
MuscleBDNF+/+ animal. (A) Representative confocal photomicrograph (60X) showing
TrkB (green), VAChT (red), and AChR labeled with α-BTX (cyan) expression in gastroc
tissue. (B) Imaris (Bitplane) rendered surfaces for TrkB (green), VAChT (red), and
AChR (cyan) expression. (C) Colocalization of TrkB and VAChT in the presynaptic
terminals of NMJs. (D) Colocalization of TrkB with AChR in the postsynaptic terminals
of NMJs.
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A.

B.

C.

D.

Figure 27. Evaluation of p-TrkB expression in gastroc-associated NMJs of 120d
MuscleBDNF-/- animal. (A) Representative confocal photomicrograph (60X) showing pTrkB (green), VAChT (red), and AChR labeled with α-BTX (cyan) expression in gastroc
tissue. (B) Imaris (Bitplane) rendered surfaces for p-TrkB (green), VAChT (red), and
AChR (cyan) expression. (C) Colocalization of p-TrkB and VAChT in the presynaptic
terminals of NMJs. (D) Colocalization of TrkB with AChR in the postsynaptic terminals
of NMJs.
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Results
TrkB results
In order to assess potential mechanisms underlying apparent retrograde transport
deficits in MuscleBDNF+/- and MuscleBDNF-/- mice, first, the levels of TrkB expression in
gastroc-associated NMJs of 120d animals were determined. To do this, colocalization of
the receptor with VAChT in the presynapse, and α-BTX in the postsynapse, was
measured and compared between groups.
One-way ANOVA indicated that the means for TrkB-VAChT colocalization were
significantly different [p = 0.0377, degrees of freedom (df) = 2, 21, F = 3.916]. However,
use of Bonferroni’s procedure showed that there were no significant differences in the
levels of presynaptic TrkB between groups (Figure 28): MuscleBDNF+/+ versus
MuscleBDNF+/- (t = 0.09292, p > 0.05), MuscleBDNF+/+ versus MuscleBDNF-/- (t = 2.347, p >
0.05), or MuscleBDNF+/- versus MuscleBDNF-/- (t = 2.517, p > 0.05). Although presynaptic
TrkB was no different between MuscleBDNF+/+ and MuscleBDNF+/- mice, receptor
expression in the NMJ of MuscleBDNF-/- animals appears to be half that of the other two
genotypes (Figure 28).
One-way ANOVA of postsynaptic TrkB revealed significantly different means (p
= 0.0016, df = 2, 20, F = 9.346). Bonferroni’s procedure indicated significant differences
in the knockout groups compared to controls (Figure 29): MuscleBDNF+/+ versus
MuscleBDNF+/- (t = 3.414, p < 0.01) and MuscleBDNF+/+ versus MuscleBDNF-/- (t = 4.004, p <
0.01). Whereas there were no significant differences between heterozygous and
homozygous knockouts (Figure 29): MuscleBDNF+/- versus MuscleBDNF-/- (t = 0.5900, p >
0.05). Thus, both MuscleBDNF+/- and MuscleBDNF-/- animals exhibited significant
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reductions in postsynaptic TrkB immunofluorescence compared to control MuscleBDNF+/+
mice (Figure 29).

Figure 28. TrkB immunofluorescence associated with VAChT-labeled presynaptic NMJs
in 120d mice. There were no significant differences in presynaptic TrkB expression
between groups. The variation in TrkB levels were relatively high in this assay; however,
TrkB appears to be much lower in MuscleBDNF-/- animals (n=7) compared to
MuscleBDNF+/+ (n=7) and MuscleBDNF+/- mice (n=8).
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Figure 29. TrkB immunofluorescence associated with α-BTX-labeled postsynaptic NMJs
in 120d mice. There were significant reductions in postsynaptic TrkB expression in
MuscleBDNF+/- and MuscleBDNF-/- mice compared to control animals (n=7; ** = p<0.01).
There was no significant difference in TrkB immunofluorescence between MuscleBDNF+/and MuscleBDNF-/- knockout animals.

p-TrkB results
To further evaluate the mechanisms underlying axonal transport disruptions in
MuscleBDNF+/- and MuscleBDNF-/- animals, the levels of the activated TrkB receptor were
assessed in gastroc-associated NMJs of 120d mice. Colocalization of p-TrkB with
VAChT in the presynaptic terminal, and α-BTX in the postsynaptic terminal, was
measured and compared between genotypes.
One-way ANOVA of presynaptic p-TrkB revealed significantly different means
(p < 0.0001, df = 2, 21, F = 15.69). Bonferroni’s procedure indicated significant
differences in the knockout groups compared to controls (Figure 30): MuscleBDNF+/+
versus MuscleBDNF+/- (t = 3.657, p < 0.01) and MuscleBDNF+/+ versus MuscleBDNF-/- (t =
5.523, p < 0.001). However, there were no significant differences between heterozygous
and homozygous knockouts (Figure 30): MuscleBDNF+/- versus MuscleBDNF-/- (t = 2.047, p
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> 0.05). Thus, presynaptic p-TrkB expression was found to be significantly lower in
MuscleBDNF+/- and MuscleBDNF-/- animals when compared to control mice (Figure 30).
One-way ANOVA of postsynaptic p-TrkB showed significantly different means
(p = 0.0017, df = 2, 21, F = 9.105). Again, Bonferroni’s t-test indicated significant
differences in the knockout groups compared to controls (Figure 31): MuscleBDNF+/+
versus MuscleBDNF+/- (t = 3.388, p < 0.01) and MuscleBDNF+/+ versus MuscleBDNF-/- (t =
3.971, p < 0.01). And once more, there were no significant differences between knockout
mice (Figure 31): MuscleBDNF+/- versus MuscleBDNF-/- (t = 0.7133, p > 0.05). Thus,
postsynaptic p-TrkB was significantly reduced in MuscleBDNF+/- and MuscleBDNF-/- mice
when compared to controls (Figure 31).

Figure 30. p-TrkB immunofluorescence associated with VAChT-labeled presynaptic
NMJs in 120d mice. MuscleBDNF+/- animals (n=8) had significantly reduced presynaptic
p-TrkB immunofluorescence compared to controls (n=7; ** = p<0.01). MuscleBDNF-/mice (n=7) also had significantly reduced presynaptic p-TrkB expression compared to
WT mice (*** = p<0.001). There was no significant difference in p-TrkB
immunofluorescence between MuscleBDNF+/- and MuscleBDNF-/- knockout animals.

58

Figure 31. p-TrkB immunofluorescence associated with α-BTX -labeled postsynaptic
NMJs in 120d mice. MuscleBDNF+/- animals (n=8) had significantly reduced postsynaptic
p-TrkB immunofluorescence compared to controls (n=7; ** = p<0.01). MuscleBDNF-/mice (n=7) also had significantly reduced postsynaptic p-TrkB expression compared to
WT mice (** = p<0.01). There was no significant change in postsynaptic p-TrkB
immunofluorescence between MuscleBDNF+/- and MuscleBDNF-/- animals.

Discussion
The expression of TrkB, and its activated form, p-TrkB, were evaluated in the
pre- and postsynaptic terminals of gastroc-associated NMJs of 120d mice. There were no
significant changes in the levels of presynaptic TrkB across genotypes, however,
expression in MuscleBDNF-/- animals was greatly reduced compared to other groups
(Figure 28). The equivalent levels of presynaptic TrkB immunofluorescence in
MuscleBDNF+/+ and MuscleBDNF+/- mice may be due to some type of compensatory
mechanism which accounts for the reduced, but not absent, levels of muscle-derived
BDNF in MuscleBDNF+/- animals. These heterozygous animals exhibit significantly
increased BDNF immunofluorescence at the cell soma of gastroc-associated motor
neurons (Figure 8B), and BDNF has been shown to be transported anterogradely from

59

neuron cell bodies to their terminals (Altar et al., 1997; Pomeroy, 2013). Additionally,
BDNF has been shown to trigger membrane insertion of TrkB, and BDNF-TrkB
signaling promotes anterograde axonal transport of TrkB, further supporting the
consistent levels of presynaptic TrkB between WT and MuscleBDNF+/- mice (Cheng et al.,
2011).
In the postsynapse, TrkB expression was significantly diminished in both
MuscleBDNF+/- and MuscleBDNF-/- mice compared to controls (Figure 29). These results
were anticipated, as disruption of TrkB signaling and reduced TrkB expression has been
shown to induce disassembly and fragmentation of postsynaptic AChR clusters in NMJs
of mice (Gonzalez et al., 1999; Kulakowski et al., 2011). The reduced levels of
postsynaptic TrkB expression may also explain the previously reported NMJ
fragmentation in MuscleBDNF+/- and MuscleBDNF-/- mice (Figures 6 and 7; Taisto et al.,
2013).
Evaluation of presynaptic p-TrkB expression revealed significantly reduced levels
of immunofluorescence in MuscleBDNF+/- and MuscleBDNF-/- mice compared to controls
(Figure 30). The reduction in presynaptic p-TrkB expression in MuscleBDNF+/- animals
was surprising because, as mentioned previously, these mice appear to exhibit a
compensatory mechanism whereby BDNF and TrkB are transported anterogradely from
the cell soma (Pomeroy, 2013). It is possible that BDNF from the cell body is not
sufficient, or inefficiently transported anterogradely, to adequately activate TrkB to the
same degree that muscle-derived BDNF is able to. The reduced levels of presynaptic pTrkB in MuscleBDNF-/- mice was expected, as these animals do not appear to exhibit the
same compensatory mechanism as heterozygous knockouts (Figure 8B; Pomeroy, 2013).
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Postsynaptic p-TrkB expression was found to be significantly reduced in both
MuscleBDNF+/- and MuscleBDNF-/- animals compared to control mice (Figure 31). These
results were expected, as it is likely that the combination of reduced or absent musclederived BDNF, reduced postsynaptic TrkB expression, and fragmentation of the
postsynapse leads to inhibition of TrkB activation.
These results indicate that presynaptic expression of TrkB is not significantly
impacted by reduced or absent muscle-synthesized BDNF. However, postsynaptic TrkB
expression is significantly decreased because of reduced or absent muscle-derived
BDNF. Additionally, both pre- and postsynaptic activation of TrkB is significantly
impaired due to reduced or absent muscle-synthesized BDNF, as evidenced by
significantly reduced pre- and postsynaptic p-TrkB expression in heterozygous and
homozygous knockout animals. Together, these data suggest severe impairments in both
pre- and postsynaptic BDNF-TrkB signaling at the NMJ due to reduced or absent musclesynthesized BDNF.
Because BDNF-TrkB signaling has been shown to play critical roles in axonal
transport and motor neuron health, it is important that future studies further investigate
the levels of TrkB expression as well as its activation in these transgenic mice. For
example, it would be of particular interest to evaluate the overall levels of both TrkB and
p-TrkB in gastroc tissue of MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/- animals at
various ages using enzyme-linked immunosorbent assays or other protein quantification
techniques. Additionally, it would be highly beneficial to assess the abundance of TrkB
mRNA in gastroc tissue of MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/- mice at
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varying stages of development using Northern blotting, in situ hybridization, or reverse
transcription PCR techniques.
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CHAPTER FOUR: EVALUATION AND CHARACTERIZATION OF
RETROGRADE TRANSPORT IN MICE MISSING MUSCLE-SYNTHESIZED
BDNF USING SCIATIC NERVE LIGATIONS

Introduction
Motor neurons have among the furthest reaching axonal projections of any type of
neuron, and as such, require an exhaustive system of endogenous and exogenous support
to ensure proper function and survival (Morfini et al., 2009; Maday et al., 2014;
McKenney et al., 2014; Ghiretti et al., 2016). Perhaps one of the most important facets of
these processes is axonal transport, as motor neurons must maintain continual
communication and trafficking of proteins, mitochondria, synaptic vesicles, and other
cellular components between the cell soma and the dendrites along far reaching axons
(Morfini et al., 2009). Interruptions in axonal transport have been cited as causative
factors in numerous neuromuscular diseases such as SBMA, HD, and ALS (Morfini et
al., 2009). In particular, retrograde transport – a process by which cellular materials are
packaged into vesicles in the distal synaptic terminals of neurons and transported toward
the cell body – has been characterized as a significant player in these diseases (Goldstein
and Yang, 2000; Morfini et al., 2009).
Several studies have shown the importance of neurotrophin signaling through Trk
receptors in the initiation of retrograde axonal transport. One such study measured the
direct binding of TrkB with the light and intermediate chains of dynein. Investigators
observed significant accumulations of TrkB with light and intermediate chains of dynein
following sciatic nerve ligation, which suggests an explicit association between TrkB and
dynein transport complexes (Yano et al., 2001). Additionally, TrkB activation of the
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Erk1/2 kinase pathway recruits cytoplasmic dynein to signaling endosomes for retrograde
axonal transport, while inhibition of Erk1/2 negatively affects the motility of TrkB
endosomes and their colocalization with dynein in axons (Mitchell et al., 2012). Other
studies have reported the importance of the adaptor proteins dynactin (DCTN1) and JIP3
in mediating neurotrophin-Trk receptor signaling and axonal transport (Huang et al.,
2011; McKenney et al., 2014; Sun et al., 2017).
Using Fluoro-Gold™ labeling protocols, the Ottem laboratory has demonstrated
that 30d and 120d transgenic mice with reduced (MuscleBDNF+/-) or absent (MuscleBDNF-/-)
muscle-synthesized BDNF exhibit reductions in the dendritic length of gastroc-associated
motor neurons (Pomeroy, 2013). However, as mentioned previously, this may have been
due to deficits in retrograde axonal transport rather than abnormalities in motor neuron
morphology. Subsequent experiments investigating these potential declines revealed
significantly increased accumulation of NF-H-P – a structural protein normally
transported retrogradely to the cell body for recycling – in the axons of gastroc-associated
motor neurons in MuscleBDNF+/- and MuscleBDNF-/- mice (Figure 20B; Dangremond,
2016). Additionally, following sciatic nerve ligation, 120d MuscleBDNF-/- mice display
significantly diminished accumulation of both dynactin and NF-H-P on the distal side of
the ligation site (Figures 14B and 15, respectively), suggesting marked retrograde
transport dysfunction in these mice (Dangremond, 2016).
Because of the apparent deficits in retrograde transport observed in these
transgenic mice, the present study aims to further characterize the nature of transport
dysfunction using the same sciatic nerve ligation protocol (adapted from (Katsuno et al.,
2006; Dangremond, 2016). If BDNF activation of TrkB at the presynaptic terminal is
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required for the initiation of retrograde transport of signaling endosomes, then significant
reductions in transport complex accumulation on the distal side of ligation were expected
in MuscleBDNF+/- and MuscleBDNF-/- mice when compared to control animals. In order to
assess this, following ligation, tissue was immunohistochemically labeled and the
expression of TrkB, p-TrkB, JIP3, DCTN1, and α-tubulin was evaluated to determine the
composition and accumulation of transport complexes on either side of the ligation site.
The structural protein α-tubulin was included as an internal control, because levels of this
protein should not differ proximally or distally between groups or IHC experiments.

Methods
Animals
Animals in this experiment were maintained according to the NIH Guidelines for
the Care and Use of Laboratory Animals and approved by the IACUC of Northern
Michigan University (Appendix A). A total of 21 male mice at 120d of age were used in
these studies. Mice were bred from existing colonies originally purchased from Jackson
Laboratories (Bar Harbor, Maine). WT MuscleBDNF+/+ control mice (n=7), MuscleBDNF+/heterozygous knockout mice (n=7), and MuscleBDNF-/- homozygous knockout mice (n=7)
were used in these experiments. Animals were housed in the temperature- and lightcontrolled animal facility at Northern Michigan University with a 14:10 hour light-dark
schedule (lights on from 07:00 to 21:00), and had access to food (Mazuri® Rodent Chow,
Land O’ Lakes Purina Feed LLC, Richmond, IN) and water ad libitum.
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Sciatic nerve ligations and tissue harvest and processing
This sciatic nerve ligation protocol was adapted from (Dangremond, 2016) and
(Katsuno et al., 2006). One hour prior to surgery, mice were administered the analgesics
Metacam® (meloxicam, oral, 5 mg/kg, Boehringer Ingelheim Vetmedica, Inc.,
Ridgefield, CT) and buprenorphine (subcutaneous, 2.5 mg/kg, Hospira, Inc., Lake Forest,
IL). At the time of surgery, mice were anesthetized via inhalation of IsoThesia™
(isoflurane, Henry Schein® Animal Health, Dublin, OH), and the right sciatic nerve was
exposed and tied at mid-thigh level with surgical thread (REDILON™, 6-0, 18”; MYCO
Medical, Cary, NC). For a control, the left sciatic nerve was exposed at mid-thigh, but not
ligated. The left and right incisions were closed using Reflex 7 mm stainless steel wound
clips (CellPoint Scientific, Inc., Gaithersburg, MD) and the mice were removed from the
isoflurane anesthesia. Animals were monitored for signs of distress every hour. Four
hours following surgery, mice were administered a supplemental dose of buprenorphine
(subcutaneous, 2.5 mg/kg, Hospira, Inc., Lake Forest, IL). After eight hours, mice were
euthanized via IP injection of sodium pentobarbital (250 mg/kg; Sigma-Aldrich®, St.
Louis, MO), then perfused with 25 mM PBS followed by 4% paraformaldehyde (in 25
mM PBS). The right sciatic nerve was re-exposed and removed, with at least 5 mm of
nerve on both the proximal and distal sides of the ligation site. The left, non-ligated
sciatic nerve was harvested in the same manner. The nerves were post-fixed in 4%
paraformaldehyde (in 25 mM PBS) for 1 hour, then transferred to ice-cold 20% sucrose
(in 25 mM PBS). The extracted sciatic nerves were sectioned at 14 µm using a Leica
CM1850 cryostat, mounted onto subbed slides, and alternately processed in two separate
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immunohistochemical assays to assess either TrkB or p-TrkB expression within transport
complexes.

TrkB IHC
Sciatic nerve tissue sections were chemically crosslinked to subbed slides by
incubating for 20 min in 4% paraformaldehyde (in 0.2 M phosphate buffer, pH 7.4). After
washing with 1X PBS, nerve sections were placed in blocking buffer (10% normal
donkey serum, 0.2% Triton® X-100 and 0.01% sodium azide in 1X PBS) for 1 hour.
Tissue was incubated for 48 hours (24 hr RT, 24 hr 4 °C) with the following primary
antibodies in blocking buffer: anti-TrkB (1:500, rabbit polyclonal antibody, ab18987;
Abcam, Cambridge, MA), anti-JIP3 (1:500, mouse monoclonal antibody, sc-46663; Santa
Cruz® Biotechnology, Inc., Dallas, TX), anti-DCTN1 (1:200, goat polyclonal antibody,
sc-9801; Santa Cruz® Biotechnology, Inc., Dallas, TX), and anti--tubulin (1:200,
chicken polyclonal antibody, ab89984; Abcam, Cambridge, MA). Sections were rinsed
with 1X PBS and incubated with the secondary antibody solution (0.2% Triton® X-100,
0.01% sodium azide, 1X PBS, and secondary antibodies indicated in Table 3) for 1 hour.
Similar to the gastroc IHC, different secondary antibody labeling schemes were used for
different slides, and are shown below in Table 3. Nerve sections were washed with 1X
PBS, allowed to dry, then coverslipped with ProLong® Gold antifade mounting reagent
(Molecular Probes® Life Technologies™, Eugene, OR).
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Table 3. Secondary labeling used for sciatic nerve TrkB IHC.
Fluorescent dye Secondary
Secondary
Secondary
preparation #1
preparation #2
preparation #3
DyLight™ 405 Donkey anti-chicken Donkey anti-chicken Donkey anti-chicken
(703-475-155)
(703-475-155)
(703-475-155)
Alexa Fluor® Donkey anti-mouse
Donkey anti-mouse
Donkey anti-rabbit
488 (715-545-150)
(715-545-150)
(711-545-152)
Alexa Fluor® Donkey anti-goat
Donkey anti-rabbit
Donkey anti-mouse
594 (705-585-003)
(711-585-152)
(715-585-150)
Alexa Fluor® Donkey anti-rabbit
Donkey anti-goat
Donkey anti-goat
647 (711-605-152)
(705-605-003)
(705-605-003)
Secondary antibody labeling schemes used for TrkB sciatic nerve IHC. Product numbers
are included with each secondary. All secondaries were used at 1:200 and obtained from
Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).

p-TrkB IHC
Sciatic nerve tissue sections were chemically crosslinked to subbed slides by
incubating for 20 min in 4% paraformaldehyde (in 0.2 M phosphate buffer, pH 7.4). After
washing with 1X PBS, nerve sections were placed in blocking buffer (10% normal
donkey serum, 0.2% Triton® X-100 and 0.01% sodium azide in 1X PBS) for 1 hour.
Tissue was incubated for 48 hours (24 hr RT, 24 hr 4 °C) with the following primary
antibodies in blocking buffer: anti-p-TrkB (1:500, Tyr816, rabbit polyclonal antibody,
ABN1381; MilliporeSigma, Temecula, CA), anti-JIP3 (1:500, mouse monoclonal
antibody, sc-46663; Santa Cruz® Biotechnology, Inc., Dallas, TX), anti-DCTN1 (1:200,
goat polyclonal antibody, sc-9801; Santa Cruz® Biotechnology, Inc., Dallas, TX), and
anti--tubulin (1:200, chicken polyclonal antibody, ab89984; Abcam, Cambridge, MA).
Sections were rinsed with 1X PBS and incubated with the secondary antibody solution
(0.2% Triton® X-100, 0.01% sodium azide, 1X PBS, and secondary antibodies indicated
in Table 4) for 1 hour. As with the TrkB sciatic nerve IHC, different secondary antibody
labeling schemes were used for different slides, and can be found below in Table 4.
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Nerve sections were washed with 1X PBS, allowed to dry, then coverslipped with
ProLong® Gold antifade mounting reagent (Molecular Probes® Life Technologies™,
Eugene, OR).

Table 4. Secondary antibody labeling used for sciatic nerve p-TrkB IHC.
Fluorescent dye Secondary
Secondary
Secondary
preparation #1
preparation #2
preparation #3
DyLight™ 405 Donkey anti-chicken Donkey anti-chicken Donkey anti-chicken
(703-475-155)
(703-475-155)
(703-475-155)
Alexa Fluor® Donkey anti-mouse
Donkey anti-mouse
Donkey anti-rabbit
488 (715-545-150)
(715-545-150)
(711-545-152)
Alexa Fluor® Donkey anti-goat
Donkey anti-rabbit
Donkey anti-mouse
594 (705-585-003)
(711-585-152)
(715-585-150)
Alexa Fluor® Donkey anti-rabbit
Donkey anti-goat
Donkey anti-goat
647 (711-605-152)
(705-605-003)
(705-605-003)
Secondary antibody labeling schemes used for p-TrkB sciatic nerve IHC. Product
numbers are included with each secondary. All secondaries were used at 1:200 and
purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).

Imaging, data collection, and analysis
To assess protein accumulation following ligation, 20 photomicrographs per
animal for the TrkB IHC experiment and 20 photomicrographs per animal for the p-TrkB
IHC experiment were acquired using an Olympus Fluoview FV1000 confocal laser
scanning microscope. For each experiment, these included 10 images of the segment
immediately proximal to the ligation site and 10 images of the distal portion.
Photomicrographs were collected at 10X and scanning speed, aspect ratio, digital zoom,
and step size were set at 20 s/pixel, 1024x1024, 1.6, and 4.77 µm, respectively.
Confocal images were uploaded into Bitplane’s Imaris® 3D rendering software for data
collection. Separate surfaces were created for each protein (α-tubulin, TrkB or p-TrkB,
JIP3, and DCTN1) within 500 m of the ligation site. Figure 32 shows an example of the
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rendered surfaces in the proximal portion of a ligated sciatic nerve. Total surface area
(µm2) for each protein was obtained and one-way ANOVA and post-hoc Bonferroni
procedure t-test statistical analyses were performed to determine the accumulation of αtubulin, TrkB or p-TrkB, JIP3, and DCTN1 on the proximal and distal sides of the
ligation site in experimental and control animals.

A.

B.

*

*

Figure 32. Assessment of protein accumulation on proximal side of ligated sciatic nerve
in 120d MuscleBDNF+/- mouse. (A) Representative confocal photomicrograph (10X
magnification, 1.6 digital zoom) of the proximal segment of ligated sciatic nerve with an
area isolated and measured 500 µm from the ligation site (*). (B) Imaris (Bitplane) 3D
rendered surfaces within area of measurement for α-tubulin (blue), JIP3 (green), DCTN1
(red), and TrkB (cyan).

Results
TrkB results
As TrkB-neurotrophin signaling is implicated in the formation of axonal transport
complexes, the expression of TrkB, DCTN1, and JIP3 was also evaluated in conjunction
with α-tubulin, an internal control, following sciatic nerve ligation in 120d mice. Protein
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accumulation was measured on both sides of the ligation site, in the proximal portion to
assess anterograde transport, and in the distal section to evaluate retrograde transport.
Evaluation of proximal α-tubulin with one-way ANOVA revealed that means
were not significantly different (p = 0.1892, df = 2, 20, F = 1.829). Bonferroni’s
procedure indicated no significant differences in proximal α-tubulin immunofluorescence
between groups (Figure 33A): MuscleBDNF+/+ versus MuscleBDNF+/- (t = 0.5986, p > 0.05),
MuscleBDNF+/+ versus MuscleBDNF-/- (t = 1.274, p > 0.05), and MuscleBDNF+/- versus
MuscleBDNF-/- (t = 1.873, p > 0.05). One-way ANOVA of distal α-tubulin again showed
that means were not significantly different (p = 0.1237, df = 2, 20, F = 2.352). Once
more, Bonferroni’s procedure indicated no significant differences in distal α-tubulin
immunofluorescence between groups (Figure 33B): MuscleBDNF+/+ versus MuscleBDNF+/- (t
= 0.8608, p > 0.05), MuscleBDNF+/+ versus MuscleBDNF-/- (t = 1.294, p > 0.05), and
MuscleBDNF+/- versus MuscleBDNF-/- (t = 2.154, p > 0.05). No significant differences in
proximal and distal α-tubulin expression existed between MuscleBDNF+/+, MuscleBDNF+/-,
or MuscleBDNF-/- mice.

A.

B.

Figure 33. Mean surface area (µm2) of α-tubulin immunofluorescence on the proximal
(A) and distal (B) sides of ligation in 120d mice. There were no significant differences in
α-tubulin immunofluorescence between groups for the proximal (A) and distal (B)
ligation sites.
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Analysis of proximal TrkB accumulation via one-way ANOVA indicated that
means were significantly different (p = 0.0012, df = 2, 20, F = 10.04). Bonferroni’s
procedure displayed significant differences in proximal TrkB immunofluorescence
between homozygous knockouts compared to both controls and heterozygous knockouts
(Figure 34): MuscleBDNF+/+ versus MuscleBDNF-/- (t = 4.232, p < 0.01) and MuscleBDNF+/versus MuscleBDNF-/- (t = 3.394, p < 0.01). There was no significant difference between
controls and heterozygous knockouts (Figure 34): MuscleBDNF+/+ versus MuscleBDNF+/- (t
= 0.8381, p > 0.05). Thus, proximal TrkB immunofluorescence was equivalent in
MuscleBDNF+/+ and MuscleBDNF+/- animals, but MuscleBDNF-/- mice exhibited significantly
reduced TrkB compared to the other genotypes (Figure 34).
Evaluation of distal TrkB accumulation via one-way ANOVA revealed that
means were significantly different (p < 0.0001, df = 2, 20, F = 22.04). Bonferroni’s
procedure showed no significant difference in distal TrkB immunofluorescence between
controls and heterozygous knockouts (Figure 35): MuscleBDNF+/+ versus MuscleBDNF+/- (t
= 2.600, p > 0.05). Whereas, again, there were significant differences between
homozygous knockouts compared to both controls and heterozygous knockouts (Figure
35): MuscleBDNF+/+ versus MuscleBDNF-/- (t = 6.591, p < 0.001) and MuscleBDNF+/- versus
MuscleBDNF-/- (t = 3.990, p < 0.01). Distally, TrkB appeared to exhibit a trending decline
in correlation with reductions in muscle-derived BDNF, however, MuscleBDNF-/- mice
were the only group to exhibit statistically significant reduced TrkB accumulation
compared to both controls and heterozygous knockouts (Figure 35).
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Figure 34. Mean surface area (µm2) of TrkB immunofluorescence accumulation at
proximal sciatic nerve ligation site in 120d mice. TrkB immunofluorescence was
significantly reduced in MuscleBDNF-/- mice compared to MuscleBDNF+/- and WT animals
(n=7; ** = p<0.01). There was no significant difference in TrkB expression between
MuscleBDNF+/- and WT mice.

Figure 35. Mean surface area (µm2) of TrkB immunofluorescence accumulation at distal
sciatic nerve ligation site in 120d mice. TrkB immunofluorescence was significantly
reduced in MuscleBDNF-/- mice compared to MuscleBDNF+/- and MuscleBDNF+/+ animals
(n=7; ** = p<0.01; *** = p<0.001). There was no significant difference in TrkB
expression between MuscleBDNF+/- and WT mice.
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Proximal accumulation of the adaptor protein JIP3 was assessed with one-way
ANOVA, which revealed that means were significantly different (p = 0.0003, df = 2, 20,
F = 13.53). Bonferroni’s procedure indicated significant differences between both
heterozygous and homozygous knockouts compared to controls (Figure 36):
MuscleBDNF+/+ versus MuscleBDNF+/- (t = 3.086, p < 0.05) and MuscleBDNF+/+ versus
MuscleBDNF-/- (t = 5.169, p < 0.001). Whereas there was no significant difference between
knockout groups (Figure 36): MuscleBDNF+/- versus MuscleBDNF-/- (t = 2.083, p > 0.05).
Thus, proximally, JIP3 was significantly reduced in MuscleBDNF+/- and MuscleBDNF-/animals compared to control mice (Figure 36).
Analysis of distal accumulation of JIP3 with one-way ANOVA indicated that
means were significantly different (p < 0.0001, df = 2, 20, F = 21.46). Once again,
Bonferroni’s procedure demonstrated that both knockout groups were significantly
different compared to controls (Figure 37): MuscleBDNF+/+ versus MuscleBDNF+/- (t =
4.707, p < 0.001) and MuscleBDNF+/+ versus MuscleBDNF-/- (t = 6.300, p < 0.001). Again,
there was no significant difference between knockout groups (Figure 37): MuscleBDNF+/versus MuscleBDNF-/- (t = 1.593, p > 0.05). Similar to the proximal results, JIP3
accumulation in the distal portion was significantly decreased in MuscleBDNF+/- and
MuscleBDNF-/- animals compared to control WT mice (Figure 37).
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Figure 36. Mean surface area (µm2) of JIP3 immunofluorescence accumulation at
proximal sciatic nerve ligation site in 120d mice. JIP3 immunofluorescence was
significantly reduced in MuscleBDNF+/- and MuscleBDNF-/- mice compared to MuscleBDNF+/+
animals (n=7; * = p<0.05; *** = p<0.001). There was no significant difference in JIP3
expression between MuscleBDNF+/- and MuscleBDNF-/- mice.

Figure 37. Mean surface area (µm2) of JIP3 immunofluorescence accumulation at distal
sciatic nerve ligation site in 120d mice. JIP3 immunofluorescence was significantly
reduced in MuscleBDNF+/- and MuscleBDNF-/- mice compared to MuscleBDNF+/+ animals
(n=7; *** = p<0.001). There was no significant difference in JIP3 expression between
MuscleBDNF+/- and MuscleBDNF-/- mice.
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One-way ANOVA evaluation of proximal DCTN1 accumulation indicated that
means were significantly different (p = 0.0120, df = 2, 20, F = 5.715). Bonferroni’s
procedure displayed no significant differences in heterozygous knockouts compared to
controls or between knockout groups (Figure 38): MuscleBDNF+/+ versus MuscleBDNF+/- (t
= 1.427, p > 0.05) and MuscleBDNF+/- versus MuscleBDNF-/- (t = 1.941, p > 0.05). Only
homozygous knockouts compared to controls exhibited significant changes (Figure 38):
MuscleBDNF+/+ versus MuscleBDNF-/- (t = 3.368, p < 0.05). Proximal DCTN1
immunofluorescence indicated a trending decline in BDNF-deficient mice; however, only
MuscleBDNF-/- animals exhibited a statistically significant reduction in DCTN1 compared
to control WT mice (Figure 38).
Distally, one-way ANOVA analysis of DCTN1 accumulation revealed that, again,
means were significantly different (p < 0.0001, df = 2, 20, F = 33.69). Once more,
Bonferroni’s procedure indicated that both knockout groups were significantly different
compared to controls (Figure 39): MuscleBDNF+/+ versus MuscleBDNF+/- (t = 5.039, p <
0.001) and MuscleBDNF+/+ versus MuscleBDNF-/- (t = 8.131, p < 0.001). However, distally,
there was a significant difference in DCTN1 accumulation between knockout groups
(Figure 39): MuscleBDNF+/- versus MuscleBDNF-/- (t = 3.092, p < 0.05). Thus, both
MuscleBDNF+/- and MuscleBDNF-/- animals had dramatically reduced DCTN1 accumulation
compared to controls, and, additionally, DCTN1 accumulation was significantly reduced
in MuscleBDNF-/- animals compared to MuscleBDNF+/- mice (Figure 39).
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Figure 38. Mean surface area (µm2) of DCTN immunofluorescence accumulation at
proximal sciatic nerve ligation site in 120d mice. DCTN1 immunofluorescence was
significantly reduced in MuscleBDNF-/- mice compared to MuscleBDNF+/+ animals (n=7;
* = p<0.05). There were no significant differences in DCTN1 expression between
MuscleBDNF+/+ and MuscleBDNF+/- animals, or MuscleBDNF+/- and MuscleBDNF-/- mice.

Figure 39. Mean surface area (µm2) of DCTN immunofluorescence accumulation at
distal sciatic nerve ligation site in 120d mice. DCTN1 immunofluorescence was
significantly reduced in MuscleBDNF+/- and MuscleBDNF-/- mice compared to MuscleBDNF+/+
animals (n=7; *** = p<0.001). DCTN1 expression was also significantly reduced in
MuscleBDNF-/- mice compared to MuscleBDNF+/- animals (* = p<0.05).
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p-TrkB results
To further investigate the potential retrograde transport disruptions in
MuscleBDNF+/- and MuscleBDNF-/- mice, and help characterize the role of TrkB-BDNF
signaling in axonal transport, the expression of p-TrkB, JIP3, and DCTN1 were assessed
along with α-tubulin in ligated sciatic nerves of 120d animals.
Analysis of proximal α-tubulin with one-way ANOVA revealed that means were
not significantly different (p = 0.5313, df = 2, 20, F = 0.6552). Bonferroni’s procedure
indicated no significant differences in proximal α-tubulin immunofluorescence between
groups (Figure 40A): MuscleBDNF+/+ versus MuscleBDNF+/- (t = 0.9901, p > 0.05),
MuscleBDNF+/+ versus MuscleBDNF-/- (t = 0.002612, p > 0.05), and MuscleBDNF+/- versus
MuscleBDNF-/- (t = 0.9927, p > 0.05). Evaluation of distal α-tubulin with one-way
ANOVA showed that means were not significantly different (p = 0.2933, df = 2, 20, F =
1.314). Bonferroni’s procedure indicated no significant differences in distal α-tubulin
immunofluorescence between groups (Figure 40B): MuscleBDNF+/+ versus MuscleBDNF+/- (t
= 1.552, p > 0.05), MuscleBDNF+/+ versus MuscleBDNF-/- (t = 0.3704, p > 0.05), and
MuscleBDNF+/- versus MuscleBDNF-/- (t = 1.182, p > 0.05). On both the proximal and distal
portions of ligation, there were no significant differences in α-tubulin
immunofluorescence between groups (Figures 40A and 40B, respectively). Mean surface
area values for α-tubulin were very similar among both TrkB and p-TrkB IHC
experiments (Figures 33 and 40).
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A.

B.

Figure 40. Mean surface area (µm2) of α-tubulin immunofluorescence on the proximal
(A) and distal (B) sides of ligation in 120d mice. There were no significant differences in
α-tubulin immunofluorescence between groups for the proximal (A) and distal (B)
ligation sites.

Analysis of proximal p-TrkB accumulation via one-way ANOVA indicated that
means were significantly different (p < 0.0001, df = 2, 20, F = 22.39). Bonferroni’s
procedure displayed significant differences in proximal p-TrkB immunofluorescence
between all groups (Figure 41): MuscleBDNF+/+ versus MuscleBDNF+/- (t = 3.232, p < 0.05),
MuscleBDNF+/+ versus MuscleBDNF-/- (t = 6.691, p < 0.001), and MuscleBDNF+/- versus
MuscleBDNF-/- (t = 3.459, p < 0.01). Thus, mean surface area of proximal p-TrkB
immunofluorescence was significantly reduced in MuscleBDNF+/- animals compared to
controls, and MuscleBDNF-/- mice exhibited significantly decreased p-TrkB compared to
both MuscleBDNF+/+ and MuscleBDNF+/- animals (Figure 41).
Evaluation of distal p-TrkB accumulation via one-way ANOVA revealed that
once more, means were significantly different (p < 0.0001, df = 2, 20, F = 34.18). Again,
Bonferroni’s procedure indicated significant differences in distal p-TrkB
immunofluorescence between all groups (Figure 42): MuscleBDNF+/+ versus MuscleBDNF+/(t = 3.866, p < 0.01), MuscleBDNF+/+ versus MuscleBDNF-/- (t = 8.262, p < 0.001), and
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MuscleBDNF+/- versus MuscleBDNF-/- (t = 4.396, p < 0.01). Distal p-TrkB accumulation was
significantly reduced in MuscleBDNF+/- mice compared to controls, and significantly
decreased in MuscleBDNF-/- animals compared to both control and MuscleBDNF+/- mice
(Figure 42). Altogether, p-TrkB accumulation was statistically different both proximally
and distally among all animal groups (Figures 41 and 42).

Figure 41. Mean surface area (µm2) of p-TrkB immunofluorescence accumulation at
proximal sciatic nerve ligation site in 120d mice. p-TrkB immunofluorescence was
significantly reduced in MuscleBDNF-/- mice compared to MuscleBDNF+/- and WT animals
(n=7; ** = p<0.01; *** = p<0.001). p-TrkB expression was also significantly diminished
in MuscleBDNF+/- animals compared to MuscleBDNF+/+ mice (* = p<0.05).
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Figure 42. Mean surface area (µm2) of p-TrkB immunofluorescence accumulation at
distal sciatic nerve ligation site in 120d mice. p-TrkB immunofluorescence was
significantly reduced in MuscleBDNF+/- and MuscleBDNF-/- mice compared to WT animals
(n=7; ** = p<0.01; *** = p<0.001). p-TrkB expression was also significantly decreased
in MuscleBDNF-/- animals compared to MuscleBDNF+/- mice.

Proximal accumulation of JIP3 was assessed with one-way ANOVA, which
showed that means were significantly different (p = 0.0022, df = 2, 20, F = 8.776).
However, Bonferroni’s procedure indicated significant differences only in homozygous
knockouts compared to controls (Figure 43): MuscleBDNF+/+ versus MuscleBDNF-/- (t =
4.171, p < 0.01). Whereas there were no significant differences in the heterozygous
knockouts compared to controls, or between knockout groups (Figure 43): MuscleBDNF+/+
versus MuscleBDNF+/- (t = 1.741, p > 0.05) and MuscleBDNF+/- versus MuscleBDNF-/- (t =
2.430, p > 0.05). Proximally, JIP3 was significantly reduced only in MuscleBDNF-/animals compared to control mice, but there appeared to be a trending decline in JIP3
expression that correlated with decreases in muscle-derived BDNF (Figure 43).
Analysis of distal JIP3 accumulation using one-way ANOVA showed once more
that means were significantly different (p = 0.0002, df = 2, 20, F = 14.22). Again,
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Bonferroni’s procedure demonstrated that both knockout groups were significantly
different compared to controls (Figure 44): MuscleBDNF+/+ versus MuscleBDNF+/- (t =
3.391, p < 0.01) and MuscleBDNF+/+ versus MuscleBDNF-/- (t = 5.260, p < 0.001). Again,
there was no significant difference between knockout groups (Figure 44): MuscleBDNF+/versus MuscleBDNF-/- (t = 1.869, p > 0.05). Similar to the JIP3 results in the TrkB IHC
experiment (Figures 36 and 37), both MuscleBDNF+/- and MuscleBDNF-/- mice displayed
significantly reduced JIP3 immunofluorescence compared to controls (Figure 44).

Figure 43. Mean surface area (µm2) of JIP3 immunofluorescence accumulation at
proximal sciatic nerve ligation site in 120d mice. JIP3 immunofluorescence was
significantly reduced in MuscleBDNF-/- mice compared to MuscleBDNF+/+ animals (n=7; **
= p<0.01). There were no significant differences in JIP3 expression between
MuscleBDNF+/+ and MuscleBDNF+/- mice, or MuscleBDNF+/- and MuscleBDNF-/- animals.
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Figure 44. Mean surface area (µm2) of JIP3 immunofluorescence accumulation at distal
sciatic nerve ligation site in 120d mice. JIP3 immunofluorescence was significantly
reduced in MuscleBDNF+/- and MuscleBDNF-/- mice compared to MuscleBDNF+/+ animals
(n=7; ** = p<0.01; *** = p<0.001). There was no significant difference in JIP3
expression between MuscleBDNF+/- and MuscleBDNF-/- mice.

Evaluation of proximal DCTN1 accumulation using one-way ANOVA showed
that means were significantly different (p = 0.0024, df = 2, 20, F = 8.557). However,
Bonferroni’s procedure indicated that proximal DCTN1 accumulation was significantly
reduced only in homozygous knockouts compared to both control and heterozygous
knockout animals (Figure 45): MuscleBDNF+/+ versus MuscleBDNF-/- (t = 3.984, p < 0.01)
and MuscleBDNF+/- versus MuscleBDNF-/- (t = 2.957, p < 0.05). Whereas once more, there
was no difference between control and heterozygous mice (Figure 45): MuscleBDNF+/+
versus MuscleBDNF+/- (t = 1.027, p > 0.05). Proximally, DCTN1 accumulation was
significantly reduced in MuscleBDNF-/- animals compared to both controls and
heterozygous knockouts (Figure 45).
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One-way ANOVA assessment of distal DCTN1 accumulation again showed that
means were significantly different (p < 0.0001, df = 2, 20, F = 20.39). Similar to the
results from the TrkB IHC experiment, Bonferroni’s procedure indicated that DCTN1
immunofluorescence was significantly different between all groups (Figure 46):
MuscleBDNF+/+ versus MuscleBDNF+/- (t = 2.895, p < 0.05), MuscleBDNF+/+ versus
MuscleBDNF-/- (t = 6.376, p < 0.001), and MuscleBDNF+/- versus MuscleBDNF-/- (t = 3.482, p
< 0.01). Thus, nearly identical to the TrkB IHC experiment results (Figure 39), distal
DCTN1 accumulation was significantly reduced in both MuscleBDNF+/- and MuscleBDNF-/animals compared to controls, and significantly decreased in MuscleBDNF-/- animals
compared to MuscleBDNF+/- mice (Figure 46).

Figure 45. Mean surface area (µm2) of DCTN immunofluorescence accumulation at
proximal sciatic nerve ligation site in 120d mice. DCTN1 immunofluorescence was
significantly reduced in MuscleBDNF-/- mice compared to MuscleBDNF+/- and MuscleBDNF+/+
animals (n=7; * = p<0.05; ** = p<0.01). There was no significant difference in DCTN1
expression between MuscleBDNF+/+ and MuscleBDNF+/- mice.
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Figure 46. Mean surface area (µm2) of DCTN immunofluorescence accumulation at
distal sciatic nerve ligation site in 120d mice. DCTN1 immunofluorescence was
significantly reduced in MuscleBDNF+/- and MuscleBDNF-/- mice compared to MuscleBDNF+/+
animals (n=7; * = p<0.05; *** = p<0.001). DCTN1 expression was also significantly
decreased in MuscleBDNF-/- mice compared to MuscleBDNF+/- animals (** = p<0.01).

Discussion
In order to assess potential disruptions in axonal transport due to reduced or
absent muscle-synthesized BDNF, accumulation of transport complex-associated proteins
was measured immediately proximally and distally to the sciatic nerve ligation site in
120d transgenic mice. Two separate but very similar experiments were performed to
evaluate the expression of α-tubulin, JIP3, and DCTN1 along with TrkB, or its activated
form, p-TrkB. These results, in conjunction with prior ligation studies conducted by the
Ottem lab, help to better characterize anterograde and retrograde axonal transport in
MuscleBDNF deficient mice.
In each experiment, both proximally and distally, the mean surface area of
α-tubulin immunofluorescence was not significantly different between animal groups
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(Figures 33 and 40). In fact, the values appeared to be very similar across the board,
indicating a high degree of consistency in the IHC assays and Imaris® data collection
between the two experiments.
Proximal to the ligation site, TrkB expression was equivalent in MuscleBDNF+/+
and MuscleBDNF+/- mice, but significantly reduced in MuscleBDNF-/- animals compared to
both groups (Figure 34). These findings are consistent with the previous results for TrkB
immunofluorescence in presynaptic terminals of gastroc-associated NMJs (Figure 28). As
mentioned earlier, BDNF is transported anterogradely from neuron cell bodies to their
terminals and, at 120d of age, heterozygous knockout mice display significantly
increased BDNF immunofluorescence at the cell soma of gastroc-associated motor
neurons (Figure 8B; Altar et al., 1997; Pomeroy, 2013). BDNF has been shown to
promote the anterograde axonal transport and trigger membrane insertion of TrkB, which
may explain the equivalent levels of TrkB accumulation on the proximal side of ligation
in MuscleBDNF+/+ and MuscleBDNF+/- mice (Cheng et al., 2011). BDNF also regulates the
surface expression of TrkB, which could explain the equivalent levels in MuscleBDNF+/+
and MuscleBDNF+/- mice, and the reduced levels in MuscleBDNF-/- animals (Haapasalo et al.,
2002). Conversely, the BDNF gene has multiple promoters and differential splicing
patterns which control the expression and trafficking of BDNF, so an increase of BDNF
at the cell soma does not necessarily mean increased anterograde transport of BDNF
(Timmusk et al., 1993; Aid et al., 2007). Additionally, JIP3 is significantly reduced in
MuscleBDNF+/- and MuscleBDNF-/- mice compared to controls (Figure 36). Because this
adaptor protein is essential for the anterograde transport of TrkB, it is somewhat
surprising to see a reduction in TrkB accumulation on the proximal side of ligation only
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in homozygous knockout mice (Huang et al., 2011; Sun et al., 2017). A previous study
found that TrkB expression is upregulated in the spinal cord following sciatic nerve
ligation, which could account for the increased accumulation of TrkB in MuscleBDNF+/mice (Narita et al., 2000). However, in the experiment by Narita and colleagues, the
sciatic nerve was ligated for 14d, while in the present study, the sciatic nerve was ligated
for only 8 hours. Thus, it is unlikely that any significant changes in TrkB expression in
the spinal cord happened during this time period (Narita et al., 2000). Additionally, any
changes in TrkB expression would have occurred in all genotypes, and therefore would
be negligible.
In the distal portion of ligated sciatic nerve, TrkB immunofluorescence was
significantly reduced in MuscleBDNF-/- animals compared to MuscleBDNF+/+ and
MuscleBDNF+/- mice (Figure 35). While the levels of TrkB accumulation were not
statistically different, TrkB did appear to be slightly lower in MuscleBDNF+/- mice
compared to controls. These data do not deviate from previous results, as the levels of
TrkB were found to be roughly equivalent in the presynaptic terminals of gastrocassociated motor neurons in MuscleBDNF+/+ and MuscleBDNF+/- mice. In addition,
endosomal transport of TrkB by dynein-dynactin complexes from an equivalent starting
pool should elicit a consistent level of protein accumulation as long as transport
mechanisms are intact (Figure 28). Previous findings indicated disrupted retrograde
transport only in MuscleBDNF-/- animals, which, combined with the decreased levels of
TrkB in presynaptic terminals of gastroc-associated NMJs, likely accounts for reduced
accumulation of the receptor on the distal side of ligation in these mice (Figures 14 and
15; Dangremond, 2016).
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Assessment of p-TrkB accumulation on the proximal side of ligation revealed
significant reductions in MuscleBDNF+/- and MuscleBDNF-/- mice compared to controls, and
in MuscleBDNF-/- animals compared to MuscleBDNF+/- mice (Figure 41). In theory, with
equivalent amounts of TrkB transported anterogradely in MuscleBDNF+/+ and
MuscleBDNF+/- mice, combined with increased BDNF expression at the cell soma in
MuscleBDNF+/- animals, comparable levels of p-TrkB accumulation were expected
between WT animals and heterozygous knockouts (Figures 8 and 34; Pomeroy, 2013).
However, studies using neuroblastoma cells and primary hippocampal neurons have
demonstrated that BDNF differentially regulates the surface expression of TrkB based on
treatment times, which may have had an influence on the levels of p-TrkB accumulation
(Haapasalo et al., 2002). Additionally, as previously mentioned, the BDNF gene has
multiple promoters and splicing patterns which direct the expression and trafficking of
BDNF (Timmusk et al., 1993; Aid et al., 2007). Thus, the increased BDNF
immunofluorescence observed in the cell soma of heterozygous knockouts may have no
effect on the activation and transport of TrkB, leading to significantly decreased levels of
p-TrkB in these mice.
On the distal side of the ligation site, p-TrkB accumulation was significantly
reduced in MuscleBDNF+/- mice compared to controls, and MuscleBDNF-/- animals compared
to both WT and heterozygous knockout mice (Figure 42). These results could be
explained by a number or combination of factors. The most apparent being, a lack – or
absence – of BDNF in muscle leads to reduced TrkB receptor activation in the
presynaptic terminal which leads to a decrease in p-TrkB accumulation at the distal
ligation site, as BDNF stimulation has been shown to be required for the initiation of
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retrograde transport of TrkB (Heerssen et al., 2004; Mitchell et al., 2012). Another
plausible cause may be reduced JIP3 expression observed in MuscleBDNF+/- and
MuscleBDNF-/- mice, as JIP3 has been shown to be essential for BDNF-induced retrograde
signaling of TrkB (Huang et al., 2011; Sun et al., 2017). One other potential source for
the reductions observed in MuscleBDNF+/- and MuscleBDNF-/- mice may be due to
impairments in retrograde transport, as discussed below.
Proximally, JIP3 accumulation was significantly reduced in both MuscleBDNF+/and MuscleBDNF-/- mice compared to controls in the TrkB IHC (Figure 36) and also
significantly diminished in MuscleBDNF-/- mice in the p-TrkB IHC (Figure 43). The
anterograde axonal delivery of TrkB is mediated by kinesin-1, which directly associates
with TrkB via interaction with JIP3 (Huang et al., 2011; Sun et al., 2017). The binding of
JIP3 to kinesin-1 is essential for TrkB axonal transport in the anterograde direction (Sun
et al., 2017). Thus, observed decreases in JIP3 accumulation on the proximal side may
account for the reduced anterograde transport of TrkB in MuscleBDNF-/- mice (Figure 34).
These data suggest impairments in anterograde axonal transport or in the assembly of
anterograde transport complexes in MuscleBDNF deficient animals.
On the distal side of the ligation site, JIP3 accumulation was significantly
decreased in MuscleBDNF+/- and MuscleBDNF-/- mice compared to controls in both the TrkB
and p-TrkB IHC experiments (Figures 37 and 44, respectively). Given that JIP3 has been
shown to be a vital adaptor protein for axonal transport and essential for BDNF-induced
TrkB retrograde signaling, these results verify the critical importance of musclesynthesized BDNF for the initiation of retrograde transport and assembly of transport
complexes (Huang et al., 2011; Sun et al., 2017). The impairments in JIP3’s ability to
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help bind retrograde transport complexes to motor proteins due to diminished or lack of
muscle-derived BDNF may account for the decreased accumulation of TrkB and p-TrkB,
as mentioned previously, and DCTN1, discussed below, in MuscleBDNF deficient mice.
On the proximal side of the ligation site, DCTN1 accumulation was significantly
reduced in MuscleBDNF-/- mice compared to controls in the TrkB IHC (Figure 38). In the
p-TrkB IHC, DCTN1 was significantly decreased in MuscleBDNF-/- animals when
compared to both heterozygous knockouts and controls (Figure 45). These results are in
conflict with the findings from Dangremond, 2016, where DCTN1 accumulation was
significantly increased in MuscleBDNF+/- and MuscleBDNF-/- mice when compared to
control animals (Figure 18). The outcome of the previous study suggested potentially
upregulated anterograde axonal transport in MuscleBDNF knockout mice (Dangremond,
2016). However, the combined results for TrkB, p-TrkB, JIP3, and DCTN1 from the
present experiments indicate impairments in anterograde transport due to decreased levels
of muscle-derived BDNF, as JIP3 and DCTN1 are integral proteins for the assembly of
transport complexes (Huang et al., 2011; Moughamian and Holzbaur, 2012; Moughamian
et al., 2013; Sun et al., 2017). The discrepancies between the previous and present results
may be due to a number of factors. However, the most plausible explanation is variability
in the IHC staining and Imaris® data collection techniques in the previous study, as there
was no evaluation of an internal control such as α-tubulin. These variations may have
been due to multiple research assistants helping with experimental techniques in the
previous study, while all of the staining and data collection in the present study was
conducted by a single researcher.
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Distally, the accumulation of DCTN1 was significantly reduced in MuscleBDNF+/and MuscleBDNF-/- mice when compared to controls, and in MuscleBDNF-/- mice compared
to MuscleBDNF+/- animals in the TrkB experiment (Figure 39). The results for DCTN1
immunofluorescence on the distal side of ligation were identical in the p-TrkB
experiment (Figure 46). These data, in association with the results for TrkB, p-TrkB, and
JIP3 accumulation, suggest significant deficiencies in retrograde axonal transport
mechanisms and retrograde neurotrophin signaling due to a lack or absence of musclesynthesized BDNF.
The results for the TrkB and p-TrkB IHC experiments are modeled in Figures 47
and 48 below.
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A.

Control (MuscleBDNF+/+)

Legend

B.

Heterozygous knockout
(MuscleBDNF+/-)

C.

Homozygous knockout
(MuscleBDNF-/-)

Figure 47. Summary of sciatic nerve ligation protein accumulation results for TrkB IHC
experiment. Results for MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/- animals are
shown in (A), (B), and (C), respectively. Accumulation of anterogradely transported
TrkB is represented by the purple filled shape, JIP3 by light green, and DCTN1 by dark
green. Accumulation of retrogradely transported TrkB is represented by the red filled
shape, JIP3 by orange, and DCTN1 by yellow. Anterograde transport of JIP3 was
significantly reduced in heterozygous knockouts (B) compared to controls (A).
Retrograde transport of JIP3 and DCTN1 was significantly decreased in heterozygous
knockouts (B) compared to controls (A). Anterograde transport of TrkB was significantly
reduced in homozygous knockouts (C) compared to controls (A) and heterozygous
knockouts (B). Anterograde transport of JIP3 and DCTN1 was significantly reduced in
homozygous knockouts (C) compared to controls (A). Retrograde transport of JIP3 was
significantly reduced in homozygous knockouts (C) compared to controls (A).
Retrograde transport of TrkB and DCTN1 was significantly decreased in homozygous
knockouts (C) compared to both controls (A) and heterozygous knockouts (B).
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A.

Control (MuscleBDNF+/+)

B.

Heterozygous knockout
(MuscleBDNF+/-)

C.

Homozygous knockout
(MuscleBDNF-/-)

Legend

Figure 48. Summary of sciatic nerve ligation protein accumulation results for p-TrkB
IHC experiment. Results for MuscleBDNF+/+, MuscleBDNF+/-, and MuscleBDNF-/- animals are
shown in (A), (B), and (C), respectively. Accumulation of anterogradely transported pTrkB is represented by the purple filled shape, JIP3 by light green, and DCTN1 by dark
green. Accumulation of retrogradely transported p-TrkB is represented by the red filled
shape, JIP3 by orange, and DCTN1 by yellow. Anterograde transport of p-TrkB was
significantly reduced in heterozygous knockouts (B) compared to controls (A), while
transport of JIP3 was reduced, but not significantly different, in heterozygous knockouts
(B) compared to controls (A). Retrograde transport of p-TrkB, JIP3, and DCTN1 was
significantly decreased in heterozygous knockouts (B) compared to controls (A).
Anterograde and retrograde transport of p-TrkB and DCTN1 was significantly reduced in
homozygous knockouts (C) compared to both controls (A) and heterozygous knockouts
(B). Anterograde and retrograde transport of JIP3 was significantly decreased in
homozygous knockouts (C) compared to controls (A).
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Together, the results of the present study indicate the significance of musclesynthesized BDNF, and BDNF-TrkB signaling, for both anterograde and retrograde
axonal transport. The results for the TrkB and p-TrkB IHC experiments are depicted in
Figures 47 and 48, respectively. The consistency of α-tubulin immunofluorescence
proximally and distally across all genotypes for both experiments indicates uniform IHC
staining techniques and Imaris® data collection procedures.
The accumulation of every labeled protein was significantly reduced in
MuscleBDNF-/- mice compared to control animals both proximally and distally. Moreover,
proximally and distally, TrkB and p-TrkB accumulation was significantly reduced in
MuscleBDNF-/- mice compared to MuscleBDNF+/- animals. In the TrkB experiment, DCTN1
was significantly reduced in MuscleBDNF-/- animals compared to MuscleBDNF+/- mice on
the distal side of ligation, but not proximally. On the other hand, DCTN1 accumulation in
the p-TrkB experiment was significantly reduced in MuscleBDNF-/- mice compared to
MuscleBDNF+/- animals both proximally and distally. The lack of significant differences in
JIP3 accumulation between MuscleBDNF+/- and MuscleBDNF-/- animals suggest that a
certain level or threshold of muscle-synthesized BDNF is required to ensure the proper
function of JIP3, because similar levels of JIP3 accumulation were observed with reduced
and absent muscle-derived BDNF. The other proteins, TrkB, p-TrkB, and DCTN1, do not
display the same threshold requirement, exhibiting significantly different levels of
accumulation between MuscleBDNF+/- and MuscleBDNF-/- mice.
Evaluation of protein accumulation in MuscleBDNF+/- animals revealed a similar,
but slightly different story. Both proximally and distally, TrkB accumulation was
equivalent with controls animals, while p-TrkB accumulation was significantly reduced
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compared to controls. In the TrkB experiment, JIP3 accumulation was significantly
reduced in MuscleBDNF+/- animals compared to controls on both the proximal and distal
sides of ligation. Alternatively, JIP3 accumulation in the p-TrkB experiment was
significantly reduced in MuscleBDNF+/- mice compared to controls distally, but not
proximally. In both IHC experiments, DCTN1 accumulation on the proximal side of
ligation was not significantly different from control animals, while distally, DCTN1
accumulation was significantly reduced in MuscleBDNF+/- animals compared to controls.
The slightly differing results between the two IHC experiments suggest that while axonal
transport mechanisms are attempting to function normally, the reduced levels of musclederived BDNF in these animals are not adequate to properly drive anterograde and
retrograde transport. Additionally, retrograde transport appears to be more severely
impaired than anterograde transport in MuscleBDNF+/- animals. This is evidenced by the
far fewer instances of significant changes from control animals on the proximal side of
ligation. On the proximal side, only two out of the six proteins assessed were
significantly different in MuscleBDNF+/- mice compared to control animals, while distally,
five out of six were significantly different compared to controls.
These data suggest significant impairments in anterograde and retrograde axonal
transport due to a lack of muscle-derived BDNF and the importance of BDNF-TrkB
signaling in these transport mechanisms. Reduced accumulation of protein on the
proximal side of ligation indicates that anterograde transport mechanisms are impaired
and that TrkB activation and signaling pathways are significantly reduced at the cell
body. Additionally, TrkB activation and signaling is also inhibited at the distal axon,
evidenced by the dysfunctional retrograde transport and decreased accumulation of
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protein on the distal side of ligation. Furthermore, JIP3 appears to exhibit a threshold
requirement for the amount of BDNF needed to ensure proper functionality, as reduced
and absent muscle-synthesized BDNF elicit equivalent levels of JIP3 accumulation.
These results also indicate that perhaps ligation of the sciatic nerve was not particularly
needed, and protein assays could have been used instead to determine expression levels
of α-tubulin, TrkB, p-TrkB, JIP3, and DCTN1 in experimental animals. However, the
ligation was important because it revealed that retrograde transport appears to be more
severely impaired than anterograde transport in MuscleBDNF+/- mice. Future studies should
further characterize the apparent axonal transport defects in mice missing musclesynthesized BDNF by assessing BDNF-TrkB downstream signaling cascades at the cell
soma and NMJ. It may be beneficial to compare mRNA levels of TrkB, JIP3, and DCTN
in motor neurons of MuscleBDNF deficient mice at varying stages of development. This
would help determine whether transport defects are occurring because of decreased
synthesis of essential transport complex proteins, or if there are post-translational
mechanisms leading to reductions in axonal transport. Additionally, it would be of
interest to evaluate other critical adaptor proteins to determine if axonal transport deficits
are due to disruptions in the assembly of transport complexes.
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CHAPTER FIVE: SUMMARY AND CONCLUSIONS

Axonal transport is the process by which cellular components are packaged into
vesicles and transported by motor proteins either from the cell soma to the distal
dendrites, anterogradely, or in the retrograde direction, from the dendrites back to the
soma. Defects in axonal transport, especially retrograde, have been implicated in a
number of neuromuscular diseases such as SBMA, HD, and ALS (Goldstein and Yang,
2000; Morfini et al., 2009). BDNF-TrkB signaling, DCTN1, and JIP3 have been shown
to be important for the initiation of axonal transport (Huang et al., 2011; Mitchell et al.,
2012; Moughamian et al., 2013; McKenney et al., 2014; Sun et al., 2017).
The Ottem laboratory has utilized the Cre/lox system to generate and study mice
missing muscle-synthesized BDNF. Previous studies labeled motor neuron dendrites
using Fluoro-Gold™, a commercially available retrograde tracer molecule, and found
that dendritic length was diminished in MuscleBDNF deficient mice (Pomeroy, 2013).
These results suggested potential retrograde axonal transport dysfunction in mice missing
muscle-derived BDNF and were further investigated using sciatic nerve ligation studies.
In 120d animals, this study reported significantly impaired retrograde transport only in
MuscleBDNF-/- mice, but intact anterograde transport mechanisms in MuscleBDNF+/- and
MuscleBDNF-/- animals (Dangremond, 2016).
The present study has expanded on these findings to further characterize the
apparent retrograde transport defects in mice missing muscle-synthesized
BDNF and determine the role of muscle-derived BDNF-TrkB signaling in axonal
transport. First, the expression of TrkB and its activated form, p-TrkB, were assessed in
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the pre- and postsynaptic terminals of gastroc-associated NMJs of 120d mice. In the
presynapse, TrkB expression appeared lower in MuscleBDNF-/- animals, but was not
significantly different among genotypes (Figure 28). Postsynaptic TrkB, however, was
significantly reduced in both MuscleBDNF+/- and MuscleBDNF-/- animals compared to
controls (Figure 29). Similarly, both pre- and postsynaptic p-TrkB expression was
significantly decreased in MuscleBDNF+/- and MuscleBDNF-/- mice compared to control
animals (Figures 30 and 31, respectively). These results indicate that presynaptic
expression of TrkB is not significantly impacted by reduced or absent muscle-synthesized
BDNF, whereas postsynaptic TrkB expression is significantly decreased. Additionally,
both pre- and postsynaptic activation of TrkB is significantly impaired due to reduced or
absent muscle-synthesized BDNF, as evidenced by significantly reduced pre- and
postsynaptic p-TrkB expression in heterozygous and homozygous knockout animals.
Together, these data suggest severe impairments in both pre- and postsynaptic BDNFTrkB signaling at the NMJ due to reduced or absent muscle-synthesized BDNF.
Additionally, this study employed sciatic nerve ligation experiments to further
assess and characterize axonal transport deficits in mice missing muscle-synthesized
BDNF. In each experiment, both proximally and distally, the mean surface area of
α-tubulin immunofluorescence was nearly identical across animal groups, suggesting a
high level of consistency throughout the IHC staining and Imaris® data collection
procedures (Figures 33 and 40, respectively).
Measuring protein accumulation on the proximal side of ligation allowed for the
evaluation of axonal transport mechanisms in the anterograde direction. TrkB
accumulation was significantly reduced in MuscleBDNF-/- animals compared to
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MuscleBDNF+/- and control mice on the proximal side of ligation (Figure 34). Proximally,
p-TrkB accumulation was significantly decreased in MuscleBDNF+/- and MuscleBDNF-/animals compared to controls, and in MuscleBDNF-/- mice compared to MuscleBDNF+/animals (Figure 41). JIP3 immunofluorescence was significantly reduced in
MuscleBDNF+/- and MuscleBDNF-/- animals compared to controls in the TrkB IHC (Figure
36), significantly diminished in MuscleBDNF-/- mice compared to controls and reduced, but
not significantly, in MuscleBDNF+/- animals compared to controls in the p-TrkB IHC
(Figure 43). Proximally, DCTN1 accumulation was significantly reduced in MuscleBDNF-/animals compared to controls in the TrkB IHC, and compared to both MuscleBDNF+/- and
control mice in the p-TrkB IHC (Figures 38 and 45, respectively).
The results obtained from evaluating protein accumulation on the proximal side of
ligation demonstrate clear impairments in anterograde axonal transport mechanisms in
MuscleBDNF-/- animals, and potential disruptions in MuscleBDNF+/- mice. Because the
accumulation of every labeled protein was significantly diminished on the proximal side
of ligation in MuscleBDNF-/- mice, it is apparent that these animals are exhibiting defective
anterograde transport mechanisms. As mentioned previously, BDNF expression is
upregulated at the cell soma of gastroc-associated motor neurons in MuscleBDNF+/animals, and BDNF has been shown to be anterogradely transported as well as induce the
anterograde transport and membrane insertion of TrkB (Altar et al., 1997; Cheng et al.,
2011; Pomeroy, 2013). Because of this compensatory upregulation of BDNF at the cell
soma, it is possible that anterograde transport mechanisms are impaired in MuscleBDNF+/animals, but are masked by greatly heightened transport of TrkB-containing vesicles from
the cell body to the dendrites in these mice.
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To assess the efficacy of retrograde axonal transport mechanisms, mean surface
area of protein accumulation on the distal side of ligation was measured. TrkB
immunofluorescence was significantly diminished in MuscleBDNF-/- animals compared to
heterozygous knockout and control mice (Figure 35). Accumulation of p-TrkB was
significantly reduced in both MuscleBDNF+/- and MuscleBDNF-/- animals compared to
controls, as well as in MuscleBDNF-/- animals compared to MuscleBDNF+/- mice (Figure 42).
In both IHC stains, JIP3 immunofluorescence was significantly reduced in MuscleBDNF+/and MuscleBDNF-/- animals compared to controls (Figures 37 and 44, respectively).
Furthermore, DCTN1 accumulation was significantly decreased in MuscleBDNF+/- and
MuscleBDNF-/- animals compared to controls, and in MuscleBDNF-/- animals compared to
MuscleBDNF+/- mice for the TrkB and p-TrkB experiments (Figures 39 and 46). These data
suggest significant dysfunctions in retrograde transport mechanisms in both
MuscleBDNF+/- and MuscleBDNF-/- animals.
Together, data from the present studies indicate the importance of BDNF-TrkB
signaling for axonal transport as well as significant impairments in anterograde and
retrograde transport mechanisms because of reduced or absent muscle-derived BDNF.
The results for the TrkB and p-TrkB experiments are depicted in Figures 47 and 48,
respectively. Reduced accumulation of protein on the proximal side of ligation indicates
that anterograde transport mechanisms are impaired and that TrkB activation and
signaling pathways are significantly reduced at the cell body. Furthermore, TrkB
activation and signaling is inhibited at the distal axon as well, which is evidenced by the
dysfunctional retrograde transport and decreased accumulation of protein on the distal
side of ligation. In addition, JIP3 appeared to require a certain threshold of BDNF for
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proper functioning. Reduced and absent muscle-derived BDNF caused equivalent
accumulation of JIP3 on the proximal and distal sides of ligation, and these levels were
significantly reduced compared to controls. Retrograde transport was found to be
markedly more impaired compared to anterograde transport in MuscleBDNF+/- animals,
however, both transport mechanisms were diminished compared to controls. This
suggests that while axonal transport is attempting to proceed normally, the reduced levels
of muscle-synthesized BDNF are not adequate to ensure proper functionality of these
transport mechanisms. MuscleBDNF-/- mice exhibited major deficiencies in anterograde
and retrograde axonal transport compared to controls. Furthermore, accumulation of
TrkB, p-TrkB, and DCTN1 were significantly reduced in MuscleBDNF-/- mice compared to
MuscleBDNF+/- animals, emphasizing the importance of muscle-synthesized BDNF and
indicating a direct correlation between the level of BDNF and the transport of these
proteins.
Future studies should investigate the levels of TrkB and p-TrkB expression in
gastroc tissue of transgenic mice at varying ages using protein quantification assays. It
may be beneficial to also assess the abundance of TrkB mRNA in gastroc tissue of these
mice using Northern blotting, in situ hybridization, or reverse transcription PCR
techniques. Because of the threshold requirement potentially exhibited by JIP3, it would
be interesting to evaluate whether treatment with BDNF restores its functionality in these
knockout mice. To further characterize the apparent axonal transport defects, it would be
helpful to assess BDNF-TrkB downstream signaling cascades at the cell soma and NMJ.
It may be beneficial to compare mRNA levels of TrkB, JIP3, and DCTN in motor
neurons of these transgenic mice. This would help define whether transport defects are
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occurring because of decreased synthesis of essential transport complex proteins, or if
there are post-translational mechanisms leading to reductions in axonal transport. Finally,
it may be advantageous to evaluate other critical adaptor proteins and motor proteins to
determine if axonal transport deficits are due to disruptions in the assembly or the
motility of transport complexes.
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Application to Use Vertebrate Animals in
Research, Testing or Instruction

Application Number: 241
Date Amended
Application Received:
6/6/14
Date of Amendment
Approval: 6/27/14

General Instructions
All parts of this form can be submitted electronically to the Institutional Animal Care and
Use Committee (email: IACUC@nmu.edu), EXCEPT for the signature page. Review of
this application will commence upon receiving the electronic application, but an
application cannot be approved without all required signatures on the hardcopy signature
page (send to IACUC/Graduate Education and Research/401 Cohodas Hall). Please
contact the IACUC chair (email: IACUCChr@nmu.edu) if you have any questions.
Review Dates:
Designated Member Review of applications (appropriate for USDA Use Categories B
and C) will be completed within two weeks after receipt of the electronic application.
Full Committee Review of applications will take place on the third Friday of every
month. Applications for Full Committee Review must be electronically received by the
first Friday of the month. Applications are reviewed by the full IACUC meeting for
USDA Use Categories D and E. A USDA Use Category B or C may be reviewed at a
Full IACUC meeting if requested by an IACUC member. Detailed procedures on the
IACUC review processes are located at the IACUC website.
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I. Principal Investigator (Must be a faculty member or Department Head)
Erich N. Ottem, Ph.D.
Co- Investigator
Rebecca Dangremond, Luke VanOsdol
Department
Biology
Phone number
906. 227. 1072
Date
02/28/2014
II.

Project/Grant/Course Number and Title (If you will be using external
funds, please use the same title as the grant application; if work is for a
course, please include the number of the course, title of the course, and a title
for the work proposed)

Investigating axonal retrograde transport in motor neurons of musclesynthesized BDNF deficient mice

Funding Sources (External & Internal) External: NIH/NINDS R15 AREA Grant
Project/Course Start and End Dates March 2014 to March 2017 (three year
maximum)
Additional Funding Pending?

Yes
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No

